Meet IntiQuan Team

All IntiQuan team members
are recognized experts
in modeling & simulation

JOIN US

OUR TEAM MEMBERS HAVE EXCELLENT
EXPERTISE IN MODELING & SIMULATION, ADVANCED ANALYTICS, AND DRUG DEVELOPMENT

We combine several decades of experience in the model-based and strategy-based support of drug development programs and general application of advanced analytics to inform decision making

Henning Schmidt, PhD

Henning Schmidt, PhD

Founder & Managing Director

Bio

Expert in Model-Informed Drug Development with cross-functional domain expertise supporting various therapeutic areas with over fifteen years of experience in the field. Professional experience includes assessing all available data and information within drug development projects (nonclinical, translational, early and late clinical, registration) in the context of the current drug development questions. Perform gap analyses, devise model based strategies to address key questions, select adequate methodological approaches, hands-on execution of analyses, supervision and mentoring of more junior modelers, and communication of results. Therapeutic area experience includes oncology, dermatology, immunology, infectious diseases, respiratory, gastrointestinal, bone and muscle wasting diseases. Pharmacometric experience includes (population) PK/PD, exposure-response, survival analysis, clinical trial simulations to assess certain metrics of interest (e.g., probability of success), complex mechanistic quantitative systems pharmacology models. Software and computational experience includes more than 18 years in the development of state-of-the-art software in support of efficient modeling and simulation across areas of Systems Biology, Quantitative Systems Pharmacology, and Pharmacometrics. These tools are key to allow focusing on the drug development question to address.

Journal Articles

Helmlinger, G. et al (2019) Quantitative Systems Pharmacology: An Exemplar Model Building Workflow with Applications in Metabolic, Cardiovascular, and Oncology Drug Development, CPT Pharmacometrics Syst Pharmacol., doi: 10.1002/psp4.12426.

Schmidt, H., Radivojevic, A. (2014) Enhancing population pharmacokinetic (popPK) modeling efficiency using an integrated workflow, Journal of Pharmacokinetics and Pharmacodynamics, invited paper, 41(4)

Hallow, K.M., et al. (2014) A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: Extending the Guyton model, American Journal of Physiology, DOI: 10.1152/ajpregu.00039.2013

Sunnaker, M., Schmidt, H., Jirstrand, M., Cedersund, G. (2010) Zooming of states and parameters using a lumping approach including back-translation, BMC Systems Biology, 4(28)

Dell’Orco, D., Schmidt, H., Mariani, S, Fanelli, F. (2009) Network-level analysis of light adaptation in rod cells under normal and altered conditions, Molecular BioSystems, DOI: 10.1039/b908123b

Schmidt, H., Madsen, M., Danø, S., Cedersund, G. (2008) Complexity Reduction of Biochemical Rate Expressions, Bioinformatics, doi: 10.1093/bioinformatics/btn035

Dell’Orco, D., Schmidt, H. (2008) Mesoscopic Monte Carlo simulations of stochastic encounters between photoactivated rhodopsin and transducin in the ROS-disc membrane, Journal of Physical Chemistry, doi: 10.1021/jp709963f

Nedbal, L., Červený, J., Rascher, U., Schmidt, H. (2007) A modeling approach to understand chlorophyll fluorescence transients and complex dynamic features of photosynthesis in fluctuating light, Photosynthesis Research, 93, 223-234

Schmidt, H., Drews, G., Vera, J., Wolkenhauer, O. (2007) SBML Export Interface for the Systems Biology Toolbox for MATLAB, Bioinformatics, 23, 1297-1298

Schmidt, H. (2007) SBaddon: High Performance Simulation for the Systems Biology Toolbox for MATLAB, Bioinformatics, 23, 646-647

Danø, S., Madsen, M., Schmidt, H., Cedersund, G. (2006) Reduction of a biochemical model with preservation of its basic dynamic properties, FEBS Journal, 273, 4862-4877

Schmidt, H., Jirstrand, M., Wolkenhauer, O. (2006) Information Technology in Systems Biology, invited article for it–Information Technology, 48(3), 133-139

Schmidt, H., Jirstrand, M. (2006) Systems Biology Toolbox for MATLAB: A computational platform for research in Systems Biology, Bioinformatics, 22(4), 514-515

Ullah, M., Schmidt, H., Cho, K.-H., Wolkenhauer, O. (2006) Deterministic Modelling and Stochastic Simulation of Pathways using MATLAB, IEE Proceedings – Systems Biology, 153(2), 53-60

Schmidt, H., Jacobsen, E.W., Cho, K.-H. (2005) Identification of Small Scale Biochemical Networks Based on General Type System Perturbations, FEBS Journal, 272(9), 2141-2151

Schmidt, H., Jacobsen, E.W. (2004) Linear systems approach to analysis of complex dynamic behaviours in biochemical networks, IEE Systems Biology, 1, 149-158

Schmidt, H., Jacobsen, E.W. (2004) Identifying feedback mechanisms behind complex cell behaviour, IEEE Control Systems Magazine, 24(4), 91-102


Book Chapters

Nedbal, N., Červený, J., Schmidt, H. (2009) Scaling and Integration of Kinetic Models of C3 Photosynthesis: Towards Comprehensive E-Photosynthesis, book chapter, Photosynthesis in silico, Springer

Ericsson, A., Mojzita, D., Schmidt, H., Hohmann, S. (2008) Case study in systematic modelling: Thiamine uptake in Yeast S. cerevisiae, book chapter, Essays in Biochemistry – Systems Biology, Portland Press


Conference posters

Johnson, M., et al. (2019) Model based analysis of the effect of adavosertib, a WEE1 kinase inhibitor on olaparib exposure, ASCPT 2019 Annual Meeting, USA 

Johnson, M., et al. (2019) Population pharmacokinetics and exposure response relationship following osimertinib treatment, ASCPT 2019 Annual Meeting, USA 

Moorthy, G., et al. (2018) Population Pharmacokinetic Model of AZD8186, a Potent and Selective Inhibitor of PI3Kβδ, in Patients with Advanced Solid Tumors, ASCPT 2018 Annual Meeting, Orlando, USA

Kümmel, A., Sunnåker, M., Kaschek, D., Schmidt, H. (2017) Manage your data comfortably: Data programming and analysis using R, Eight American Conference on Pharmacometrics (ACoP), Fort Lauderdale, USA

Sokolov, V, et al. (2017) Drug-Disease modeling: a practical workflow from model development to simulations, Eight American Conference on Pharmacometrics (ACoP), Fort Lauderdale, USA

Sunnåker, M., Kümmel, A., Kaschek, D., Schmidt, H. (2017) Towards a user-friendly and powerful Modeling & Simulation environment in R – Enabling efficient work across QSP and Pharmacometrics with access to robust estimation algorithms, Eight American Conference on Pharmacometrics (ACoP), Fort Lauderdale, USA

Schmidt, H., Kaschek, D., Kümmel, A., Sunnåker, M. (2017) Systems Pharmacology Modeling in R, powered by Shiny, Eight American Conference on Pharmacometrics (ACoP), Fort Lauderdale, USA

Johnson, M., Schmidt, H., Sunnaker, M., Hamren, B., AlHuniti, N., Nayak, S., Tomkinson, H., Vishwanathan, K. (2017) Exposure response relationship of interstitial lung disease (ILD) events following Osimertinib treatment, Population Approach Group (PAGE) meeting 2017, Budapest, Hungary

Johnson, M., Schmidt, H., Sunnaker, M., Nash, T., Nayak, S., Tomkinson, H., Vishwanathan, K. (2017) Population pharmacokinetic and pharmacodynamic analysis of osimertinib, American Society of Clinical Oncology – 53rd Annual Meeting (ASCO2017), Chicago, USA

Sunnåker, M., Schmidt, H. (2016) IQM Tools: Efficient State of the Art Modeling across Pharmacometrics and Systems Pharmacology (ACoP7), Seattle, USA

Radivojevic, A., Schmidt, H. (2015) Datasets for pharmacometric analyses: internal review and standardization efforts, Sixth American Conference on Pharmacometrics (ACoP6), Arlington, VA, USA

Schmidt, H. (2015) SBPOP/mPD: Informing dose-concentration-response relationships – Application to study design and information generation based on competitor data, Population Approach Group (PAGE) meeting 2015, Hersonissos, Greece

Weber, F. Schmidt, H., Pfister, M., J v.d. Anker (2015) Pharmacometric approach to characterize key metabolites of acetaminophen in preterm and term neonates, Population Approach Group (PAGE) meeting 2015, Hersonissos, Greece

Goldhahn, J., Radivojevic, A., Tanko, L., 3, Papanicolaou, DA., Schmidt, H. (2013) Modeling rehabilitation after hip fracture, 2nd Fragility Fracture Network Congress, Berlin, Germany

Schmidt, H. (2013) The “SBPOP Package”: Efficient Support for Model Based Drug Development – From Mechanistic Models to Complex Trial Simulation, Population Approach Group (PAGE) meeting 2013, Glasgow, Scotland

Radivojevic, A., Fink, M., Steimer, J.-L., Schmidt, H. (2013) Enhancing Population PK modeling efficiency using an integrated workflow, Population Approach Group (PAGE) meeting 2013, Glasgow, Scotland

Zhudenkov, K., Helmlinger, G., Schmidt, H. (2012) Application of the SBTOOLBOX2 in drug discovery and development, Population Approach Group (PAGE) meeting 2012, Venice, Italy

Frey, S., Schmidt, H., Rateitschak, K., Beltran, G., Garcia-Salcedo, R., Elbing, K., Bosch, D., Ye, T., Hohmann, S., Wolkenhauer, O. (2009) Modelling Snf1 regulation in Saccharomyces cerevisiae, 9th International Conference on Systems Biology, Gothenburg, Sweden

Egea, J.A., Schmidt, H., Banga, J.R. (2008) A new tool for parameter estimation in nonlinear dynamic biological systems using global optimization, 9th International Conference on Systems Biology, Gothenburg, Sweden

Liebal, U.W., Schmidt, H. (2008) Sensitivity Analysis based Adaptive Search-Space Reduction for Parameter Estimation Applications, 9th International Conference on Systems Biology, Gothenburg, Sweden

Bittig, A.T., Schmidt,H. (2008) Format Overflow? Handling of Modeling Projects in Systems Biology, 9th International Conference on Systems Biology, Gothenburg, Sweden

Dell’Orco, D., Fanelli, F., Schmidt, H. (2008) Dynamic modeling of phototransduction biochemistry in vertebrate rods: from dark/light adaptation to disease, 9th International Conference on Systems Biology, Gothenburg, Sweden

Almquist, J., Schmidt, H., Lang, P., Prätzel-Wolters, D., Deitmer, J.W., Jirstrand, M., Becker, H.M. (2008) A model reduction approach to the kinetics of the monocarboxylate transporter MCT1 and carbonic anhydrase II, 9th International Conference on Systems Biology, Gothenburg, Sweden

Schmidt, H. (2008) Hierarchical Modelling of Metabolism: From Methodology to Application, ISGSB 2008, Elsinor, Denmark

Schmidt, H., Jirstrand, M., Cedersund, G. (2006) A Systematic Modelling Framework for Biochemical and Biological Systems, 7th International Conference on Systems Biology, Yokohama, Japan

Cedersund, G., Jirstrand, M., Schmidt, H. (2006) Model reduction for various levels of model development, 7th International Conference on Systems Biology, Yokohama, Japan

Jirstrand, M., Schmidt, H., Cedersund, G. (2006) Parameter Estimation Using Alternative Cost Functions, 7th International Conference on Systems Biology, Yokohama, Japan

Mojzita, D., Nahmany, A., Schmidt, H., Homann, S. (2006) Dynamic modelling of thiamine regulation in Saccharomyces cerevisiae based on High Performance Liquid Chromatography (HPLC) measurements, International Specialised Symposium on Yeasts, Helsinki, Finland

Schmidt, H., Jirstrand, M. (2005) Systems Biology Toolbox for MATLAB: A computational platform for research in Systems Biology, 6th International Conference on Systems Biology, Boston, USA

Schmidt, H., Jacobsen, E.W. (2004) On the Decomposition of Biochemical Networks, H. Schmidt and E. Jacobsen, 5th International Conference on Systems Biology, Heidelberg, Germany

Schmidt, H., Jacobsen, E.W. (2004) Identification of the dynamic structure of biochemical networks based on least squares estimation of the Jacobian, 5th International Conference on Systems Biology, Heidelberg, Germany

Schmidt, H., Jacobsen, E.W. (2003) A linear systems approach to the analysis of complex behaviours within biochemical reaction networks – application to the cell cycle, 4th International Conference on Systems Biology, Saint Louis, USA 

Anne Kümmel, PhD

Anne Kümmel, PhD

Director Consulting

Selected peer-reviewed Articles

Kümmel A., Selzer P., Siebert D., Schmidt I., Reinhard J., Götte M, Ibig-Rehm Y., Parker C. N., Gabriel D. Differentiation and visualization of diverse cellular phenotypic responses in primary high-content screening Journal of Biomolecular Screening 16(3): 338-347 2012

Kümmel A., Ewald J. C., Fendt S.-M., Jol S., Picotti P., Aebersold R., Sauer U., Zamboni N., Heinemann M. Differential glucose repression in common yeast strains in response to a HXK2 deletion. FEMS Yeast Research 10(3): 322-32, 2010

Kümmel A., Beibel M., Gehin P., Gubler H., Gabriel D., Parker C. N. Integration of multiple readouts into the Z’ factor for assay quality control Journal of Biomolecular Screening 15(1): 95-101, 2010.

Kümmel A., Panke S., Heinemann M. Systematic assignment of thermodynamic constraints in metabolic network models BMC Bioinformatics 7:512, 2006

Kümmel A., Panke S., Heinemann M. Putative regulatory sites unraveled by network-embedded thermodynamic analysis of metabolome data Molecular Systems Biology 2, 2006, doi:10.1038/msb4100074


Book chapters

Lowe P. J., Kümmel A., Vasalou C., Matsushima S., Skerjanec A. Integrated quantitation of drug-target binding, biomarkers and clinical response to support rational dose regimen selection. in ADME and translational pharmacokinetics/pharmacodynamics of therapeutic proteins: Applications in drug discovery and development. Zhou, H., Theil F.-P. Eds., John Wiley & Sons Inc.: Hoboken, New Jersey, 2015

Kümmel A., Parker C. N. The interweaving of cheminformatics and high-throughput screening in Cheminformatics and Computational Chemical Biology, Bajorath J. Ed., Humana Press/Springer: Totowa, N. J., 2010


Selected Poster and Oral Presentations at Conferences

Kümmel A., Abuhelwa A., Krause A. Try yourself! Making clinical teams explore dose response relationships in R Shiny Oral presentation @ 12th Basel M&S seminar, Basel, Switzerland, 19-20/09/2016

Kümmel A., Abuhelwa A., Krause A. PECAN, a Shiny application for calculating confidence intervals and prediction intervals for pharmacokinetic and pharmacodynamic models Poster presentation @ 25th PAGE meeting, Lisboa, Portugal, 07-10/06/2016

Kümmel A., Lowe P. Mechanism-based population PK modeling describing pharmacological effects from dose to clinical response enables mechanistics insights and projections beyond the studied treatment Poster presentation @ 7th Noordwijkerhout Symposium on Pharmacokinetics, Pharmacodynamics and Systems Pharmacology, Noordwijk, Netherlands, 23-25/04/2014

Stefan Wetzel, PhD

Stefan Wetzel, PhD

Senior Director BD and Operations

Bio

Coming Soon

  1. Coming soon
Benjamin Guiastrennec, PharmD, PhD

Benjamin Guiastrennec, PharmD, PhD

Associate Director Consulting

Bio

Dr. Benjamin Guiastrennec is an experienced pharmacometrician and R enthusiast. Over the years, he has gained experience in planning and performing PK-PD modeling and simulation analyses in various therapeutic areas from early to late drug development stages. Benjamin has a strong interest in data visualization and developed several R packages for model diagnostics such as amget, modelviz or the new xpose.

Benjamin graduated from the school of pharmacy of Montpellier (France) and obtained a master of Pharmacokinetics from the school of pharmacy of Marseille (France). He then pursued a PhD program at the university of Uppsala (Sweden) focusing on the mechanism-based modeling of processes involved in oral drug absorption. Through his education Benjamin was also part of a postdoctoral fellowship program between the university at Buffalo (NY, USA) and Novartis (NJ, USA) and had the opportunity to be an exchange student with the university of California, San Francisco (CA, USA). Benjamin joined the IntiQuan team in 2019.

Guiastrennec B, Sonne DP, Bergstrand M, Vilsbøll T, Knop FK, Karlsson MO. Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. CPT Pharmacometrics Syst. Pharmacol., 7:603–612, 2018

Guiastrennec B, Ramachandran G, Karlsson MO, Kumar AKH, Bhavani PK, Gangadevi NP, Swaminathan S, Gupta A, Dooley KE, Savic RM. Suboptimal Antituberculosis Drug

Concentrations and Outcomes in Small and HIV-Coinfected Children in India Recommendations for Dose Modifications. Clin. Pharmacol. Ther., 104(4):733–741, 2018

Guiastrennec B, Söderlind E, Richardson S, Peric A, Bergstrand M. In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status. Pharm Res, 34:847–859, 2017

Guiastrennec B, Sonne DP, Hansen M, Bagger JI, Lund A, Rehfeld JF, Alskär O, Karlsson MO, Vilsbøll T, Knop FK, Bergstrand M. Mechanism–Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake. CPTPharmacometrics Syst. Pharmacol, 5:692–700, 2016

Guiastrennec B, Wollenberg L, Forrest A and Ait–Oudhia S. AMGET, an R–Based Postprocessing Tool for ADAPT 5. CPT Pharmacometrics & Syst. Pharmacol. 2(7):1–10, 2013

Daniel Kaschek, PhD

Daniel Kaschek, PhD

Associate Director Consulting

Bio

Dr. Daniel Kaschek is an experienced modeler working in the field of Systems Biology and Computational Biology since 2008. Over the past years, he has actively worked on the developed of novel mathematical and statistical approaches to data analysis and parameter estimation in ordinary differential equations with applications in Systems Biology and Systems Pharmacology. He is an enthusiast R package developer, authoring several packages on Data Preprocessing and Dynamic Modeling.

Daniel has a background in Physics and specialized on Mathematical Physics at the University of Freiburg, Germany. For his PhD he changed field and started his research in Systems Biology and Data Analysis at the Physics department. During his PhD he covered a broad range of biological applications, e.g., in Immunology, Cancer Research or Drug-Induced Liver Injury, developing and applying diverse mathematical methods related to statistical inference, optimal control and identifiability analysis.

After his PhD, he became leader of the subgroup “Physical Methods in Systems Biology” where he worked with his team on the translation of concepts from theoretical physics to applications in Systems Biology. He joined the IntiQuan team in 2017

Selected publications:

Kaschek, D.; Sharanek, A.; Guillouzo, A.; Timmer, J. & Weaver, R. J., A dynamic mathematical model of bile acid clearance in HepaRG cells, Toxicological Sciences, Oxford University Press, 2017

Rosenblatt, M.; Timmer, J. & Kaschek, D, Customized steady-state constraints for parameter estimation in non-linear ordinary differential equation models, Frontiers in Cell and Developmental Biology, Frontiers Media SA, 2016

Maiwald, T.; Hass, H.; Steiert, B.; Vanlier, J.; Engesser, R.; Raue, A.; Kipkeew, F.; Bock, H. H.; Kaschek, D.; Kreutz, C. & Timmer, J., Driving the model to its limit: profile likelihood based model reduction PloS ONE, Public Library of Science, 2016

Kaschek, D.; Mader, W.; Fehling-Kaschek, M.; Rosenblatt, M. & Timmer, J., Dynamic Modeling, Parameter Estimation and Uncertainty Analysis in R, bioRxiv, Cold Spring Harbor Labs Journals, 2016

Hass, H.; Kreutz, C.; Timmer, J. & Kaschek, D., Fast integration-based prediction bands for ordinary differential equation models, Bioinformatics, Oxford Univ Press, 2016

Kaschek, D.; Henjes, F.; Hasmann, M.; Korf, U. & Timmer, J., Testing the pattern of AKT activation by variational parameter estimation, IEEE Life Science Letters, 2016

Kaschek, D. & Timmer, J., A unified approach to integration and optimization of parametric ordinary differential equations, Springer, 2015

Merkt, B.; Timmer, J. & Kaschek, D., Higher-order Lie symmetries in identifiability and predictability analysis of dynamic models, Physical Review E, APS, 2015

Raue, A.; Schilling, M.; Bachmann, J.; Matteson, A.; Schelke, M.; Kaschek, D.; Hug, S.; Kreutz, C.; Harms, B. D.; Theis, F. J. & others, Lessons learned from quantitative dynamical modeling in systems biology, PloS One, Public Library of Science, 2013

Fiala, G. J.; Kaschek, D.; Blumenthal, B.; Reth, M.; Timmer, J. & Schamel, W. W., Pre-clustering of the B cell antigen receptor demonstrated by mathematically extended electron microscopy, Frontiers in Immunology, Frontiers Media SA, 2013

Kreutz, C.; Raue, A.; Kaschek, D. & Timmer, J., Profile likelihood in systems biology, FEBS Journal, Wiley Online Library, 2013

Kaschek, D. & Timmer, J., A variational approach to parameter estimation in ordinary differential equations, BMC Systems Biology, BioMed Central Ltd, 2012

Pfeifer, A. C.; Kaschek, D.; Bachmann, J.; Klingmüller, U. & Timmer, J., Model-based extension of high-throughput to high-content data, BMC Systems Biology, BioMed Central Ltd, 2010

Darius Schweinoch, MSc

Darius Schweinoch, MSc

Modeling & Simulation Scientist

Bio

Darius Schweinoch is an experienced modeler, who worked on a broad range of biological and pharmaceutical research questions. Coming from an interdisciplinary background (Cell Biology (B. Sc.), Bioinformatics (M. Sc.)), Darius’ research mainly focused on the field of systems biology. In his Master studies, Darius developed models to study the hepatic clearance of uptake-limited drugs based on in vitro data and applied PBPK modeling. His PhD studies at the Institute of Bioinformatics of the University Medicine in Greifswald focused on mathematical modeling to answer research questions regarding the antiviral innate immune response and the replication of Hepatitis C Virus (HCV) under drug treatment. During this time, Darius was awarded the Add-On Fellowship for Interdisciplinary Life Science of the Joachim Herz Stiftung and worked in close collaboration with scientists from numerous backgrounds (biologists, informaticians, statisticians). He further gained hands-on experience in the analysis of biological and medical data using statistical and machine learning methods. Since August 2020, Darius is a Modeling and Simulation Scientist at IntiQuan.

Schweinoch, Darius, et al. “Mechanistic modeling explains the dsRNA length-dependent activation of the RIG-I mediated immune response.” Journal of Theoretical Biology (2020): 110336.

Karsten Kuritz, PhD

Karsten Kuritz, PhD

Modeling & Simulation Scientist

Bio

Dr. Kuritz is an experienced modeler with broad expertise in biology, dynamical systems theory and data science. At IntiQuan, he focuses on population pharmacokinetic (popPK) and population pharmacokinetic/pharmacodynamic (PK/PD) modeling as well as systems pharmacology type of modelling across all phases of drug development.

Prior to joining IntiQuan in 2021, Karsten Kuritz developed mathematical tools for the analysis of single cell data and for the control of heterogeneous cell populations.

He is passionate about innovation and excels in creatively approaching interdisciplinary problems. His training as both a biologist and control engineer/data scientist helps him to communicate and integrate computational results into project decisions.

Journal articles (peer reviewed)

Kuritz, K., Stöhr, D., Maichl, D. S., Pollak, N., Rehm, M., and Allgöwer, F. “Reconstructing temporal and spatial dynamics from single-cell pseudotime using prior knowledge of real scale cell densities”. In: Scientific Reports 10.1 (2020), p. 3619. doi: 10.1038/s41598-020-60400-z.

Colbrook, M. J., Botev, Z. I., Kuritz, K., and MacNamara, S. “Kernel density estimation with linked boundary conditions”. In: Studies in Applied Mathematics (2020). doi: 10.1111/sapm.12322.

Kuritz, K., Zeng, S., and Allgöwer, F. “Ensemble Controllability of Cellular Oscillators”. In: IEEE Control Systems Letters 3.2 (2019), pp. 296–301. doi: 10.1109/lcsys.2018.2870967.

Kuritz, K., Stöhr, D., Pollak, N., and Allgöwer, F. “On the relationship between cell cycle analysis with ergodic principles and age-structured cell population models”. In: Journal of Theoretical Biology 414 (2017), pp. 91–102. doi: 10.1016/j.jtbi.2016.11.024.

Thomaseth, C., Kuritz, K., Allgöwer, F., and Radde, N. “The circuit-breaking algorithm for monotone systems”. In: Mathematical Biosciences 284 (2017), pp. 80–91. doi: 10.1016/j.mbs.2016.09.002.

Conference proceedings (peer reviewed)

Imig, D., Kuritz, K., Pollak, N., Rehm, M., and Allgöwer, F. “Death patterns resulting from cell cycle-independent cell death”. In: IFAC-PapersOnLine 51.19 (2018). 7th Conference on Foundation of Systems Biology in Engineering FOSBE 2018, pp. 90–93. doi: 10.1016/j.ifacol.2018.09.028.

Kuritz, K., Imig, D., Dyck, M., and Allgöwer, F. “Ensemble control for cell cycle synchronization of heterogeneous cell populations”. In: IFAC-PapersOnLine 51.19 (2018). 7th Conference on Foundation of Systems Biology in Engineering FOSBE 2018, pp. 44–47. doi: 10.1016/j.ifacol.2018.09.034.

Book chapters

Kuritz, K., Halter, W., and Allgöwer, F. “Passivity-Based Ensemble Control for Cell Cycle Synchronization”. In: Emerging Applications of Control and Systems Theory: A Festschrift in Honor of Mathukumalli Vidyasagar. Ed. by R. Tempo, S. Yurkovich, and P. Misra. Cham: Springer International Publishing, 2018, pp. 1–13. doi: 10.1007/978-3-319-67068-3_1.

Conference Talks

Kuritz, K. and Allgöwer, F. “Ensemble control for cellular oscillators: One ring to rule them all”. Workshop: Analysis, Control, and Learning of Dynamic Ensemble and Population Systems. IFAC World Congress. Virtual, 2020.

Kuritz, K., Stöhr, D., Pollak, N., and Allgöwer, F. “Reconstructing dynamic processes from high dimensional snap shot data”. Int. Conf. on Systems Biology of Human Disease. Heidelberg, 2017.

Kuritz, K., Stöhr, D., Pollak, N., and Allgöwer, F. “Reconstructing dynamic processes from high dimensional snap shot data”. Int. Conf. on Systems Biology. Blacksbourg, VA, 2017.

Kuritz, K. and Allgöwer, F. “Determining protein level variations along the cell cycle from snap-shot population measurements”. Workshop on Computational Models in Biology and Medicine. Cologne, 2014.

Poster presentations (excerpt)

Kuritz, K. and Allgöwer, F. “Broadcast control of oscillating cell populations”. EMBO | EMBL Symposium: Biological Oscillators: Design, Mechanism, Function. Heidelberg, 2018.

Kuritz, K. and Allgöwer, F. “Therapy design by broadcast control of oscillating cell populations”. Curious2018 – Future Insight. Darmstadt, 2018.

Kuritz, K., Stöhr, D., Pollak, N., and Allgöwer, F. “Reconstructing dynamic processes from high dimensional snap shot data”. Int. Conf. on Systems Biology. Blacksbourg, VA, 2017.

Kuritz, K., Stöhr, D., Pollak, N., Rehm, M., and Allgöwer, F. “Reconstructing dynamic processes from high dimensional snap shot data”. CSHL 9th Single Cell Analyses Meeting. 2017.

Kuritz, K., Müller, F., Pollak, N., and Allgöwer, F. “Too Young to Die: Age Structured Population Models Capture Cell Cycle Dependent Apoptosis from Snapshot Data”. Int. Conf. on Systems Biology of Human Disease. Boston, MA, 2016.

Kuritz, K. and Allgöwer, F. “Inferring cell-cycle dependent signalling with age-structured population models”. Int. Conf. on Systems Biology of Human Disease. Heidelberg, 2015.

Kuritz, K., Radde, N., and Olayioye, M. “Multi-scale modeling reveals membrane domain variations as mechanism behind augmented ErbB receptor activation”. In: 14th International Conference on Systems Biology. Copenhagen, 2013.

Kuritz, K., Kearns, J. D., Bukhalid, R., Harms, B. D., Nielsen, U. B., and Schoeberl, B. “Deciphering paradoxical responses to RAF inhibitors – new insights in the MAPK cascade”. In: 12th International Conference on Systems Biology. Heidelberg, 2011.

Venelin Mitov, PhD

Venelin Mitov, PhD

Modeling & Simulation Scientist

Bio

Dr. Venelin Mitov is a highly skilled modeler and software engineer, holding a Ph.D. and a M.Sc. degree in Computational Biology, and a B.Sc. degree in Computer Science. His profile combines a strong mathematical and computer science background with almost a decade of experience in machine learning and statistical modelling.

Venelin has had a dynamic career path spanning both, industry and academia. His main personal strengths are his analytical mindset, combined with a motivation to excel in any professional and scientific challenge. He is a proficient R programmer (developer of a dozen of R-packages; owner of 3 CRAN packages), and he masters several other languages, including C++, Java, and Matlab. During his Ph.D. and post-doctoral studies, he has specialized in population and quantitative trait evolution models, with applications to epidemiological, macro-evolutionary, and stem-cell data. In 2019, his Ph.D. thesis entitled “Phylogenetic Comparative Methods in the Era of Big Data” has been nominated for the ETH silver medal for an outstanding Ph.D. dissertation. More about his open source research projects can be found on his portfolio web-page. 

Starting from February 2020, Venelin joined IntiQuan as a modeling and simulation scientist. In this role he conducts modeling and simulation analyses across all phases of drug discovery and development, with emphasis on:

  • Systems pharmacology models;
  • Population PK and PK/PD models;
  • Statistical analyses.
  • Mitov V, Bartoszek K., Asimomitis G, Stadler T. Fast likelihood calculation for multivariate Gaussian phylogenetic models with shifts. Theor. Popul. Biol., vol 131, pp 66-78. 2020.
  • Mitov V, Bartoszek K, Stadler T. Automatic generation of evolutionary hypotheses using mixed Gaussian phylogenetic models. PNAS USA, vol 116 no 34 pp 16921-16926. 2019.
  • Mitov V, Stadler T. Parallel likelihood calculation for phylogenetic comparative models: The SPLITT C++ library. Methods Ecol. Evol . 2041-210X.13136. 2019.
  • Mitov V, Stadler T. A Practical Guide To Estimating the Heritability of Pathogen Traits. Mol. Biol. Evol., vol 6 (9) pp e1001123. 2018.
  • Bertels F, Marzel A, Leventhal G, Mitov V, Fellay J, Günthard H F, Böni J, Yerly S, Klimkait Th, Aubert V, Battegay M, Rauch A, Cavassini M, Calmy A, Bernasconi E, Schmid P, Scherrer A, Müller V, Bonhoeffer S, Kouyos R, Regoes R, The Swiss HIV Cohort Study. Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Mol. Biol. Evol., vol 35 (1), pp 27-37. 2017.
  • Barido-Sottani J, Boskova V, Du Plessis L, Kühnert D, Magnus C, Mitov V, Müller N F, PečErska J, Rasmussen D A, Zhang C, Drummond A, Heath Tr, Pybus O G, Vaughan T G, Stadler T. Taming the BEAST—A Community Teaching Material Resource for BEAST 2. Syst. Biol., vol. 67 (1) pp. 170-174. 2017.
  • Mitov V, Claassen M. A Fused Elastic Net Logistic Regression Model for Multi-Task Binary Classification. arXiv:1312.7750. 2013.
  • Wan, C., Bachmann, N., Mitov, V. et al. Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. Nat Commun 11, 5542 (2020). https://doi.org/10.1038/s41467-020-19198-7  
Nuggehally R Srinivas PhD, FCP

Nuggehally R Srinivas PhD, FCP

Expert Consultant - External

Bio

A leader in clinical pharmacology with cross-functional domain expertise supporting various therapeutic areas (small molecules, biologics and biosimilars) with about 3 decades of experience in pharmaceutical industry. Professional experience includes rationalizing concepts, design considerations, planning, execution and analyzing discovery ADME/DMPK, nonclinical and clinical pharmacology studies. Development experience encompasses of developing 505(b)(1) and 505(b)(2) regulatory pathway programs – end to end discovery led candidate nomination, IND and clinical development up to market authorization.  Drug development experiences comprises of numerous INDs/CTAs (>70), clinical pharmacology programs to support NDA, and Biosimilar/BLA strategy. From a regulatory perspective interacted with global regulatory agencies (i.e., FDA, MCC, EMA, MHRA, TPD, TGA, DCGI etc.) for various meetings (i.e., FDA’s Type A, B and C meetings).

Publications:

  1. Srinivas NR, Quinn D, Hubbard JW and Midha KK (1987) Stereoselective disposition of methylphenidate in children with attention deficit disorder. Journal of Pharmacology and Experimental Therapeutics 241:300-306.
  2. Srinivas NR, Hubbard JW, Cooper JK and Midha KK (1988) Enantioselective gas chromatographic assay with electron capture detection for dl-fenfluramine and dl-norfenfluramine in plasma. Journal of Chromatography 433:105-117.
  3. Srinivas NR, Hubbard JW, Hawes EM, McKay G, and Midha KK (1989) Enantioselective gas chromatographic assays with electron capture detection for methoxyphenamine and its three metabolites in human urine. Journal of Chromatography 487:61-72.
  4. Srinivas NR, Cooper JK, Hubbard JW and Midha KK (1989) Isothermal capillary gas chromatography with electron capture detection of heptafluorobutyryl-l-prolyl derivatives of chiral amphetamines. Journal of Chromatography 491:262-264.
  5. Hubbard JW, Srinivas NR, Quinn D and Midha KK (1989) Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained release formulation to children with attention deficit hyperactivity disorder. Journal of Pharmaceutical Sciences 78:944-947.
  6. Srinivas NR, Hubbard JW and Midha KK (1990) Enantioselective gas chromatographic assay with electron capture detection for dl-ritalinic acid in plasma. Journal of Chromatography 530:327-336.
  7. Srinivas NR, Hubbard JW, Quinn D, Korchinski ED and Midha KK (1991) Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans. Progress in Neuro-Psychopharmacology 15:213-220.
  8. Srinivas NR (1991) Enantioselective pharmacokinetics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder and healthy adults. Ph.D. Dissertation, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  9. Srinivas NR, Lim HK, Hubbard JW and Midha KK (1991) Evidence that dogs do not model enantioselective pharmacokinetics of dl-methylphenidate in humans. Journal of Pharmaceutical Sciences 80:707-708.
  10. Srinivas NR, Hubbard JW, McKay G, Hawes EM and Midha KK (1991) In vitro hydrolysis of RR,SS-threo-Methylphenidate by blood esterases-Differential and enantioselective interspecies variability. Chirality, 3:99-103.
  11. Srinivas NR, Hubbard JW and Midha KK (1991) Enantioselective analysis of phenylisopropyl-amine drugs in saliva. Pharmaceutical Research, 8 (Suppl.), S29.
  12. Hubbard JW, Marshall BD, Srinivas NR, Bowen LL, Cooper JK, Liberman RL, and Midha KK (1992). Pharmacokinetics of fenfluramine and neuroleptics in treatment refractory schizophrenics. Drug Investigation, 4:99-111.
  13. Srinivas NR, Hubbard JW, Korchinski ED and Midha KK (1992) Stereoselective urinary pharmacokinetics of dl-threo-methylphenidate and its major metabolite in humans. Journal of Pharmaceutical Sciences, 81:747-749.
  14. Srinivas NR, Hubbard JW, Quinn D and Midha KK (1992) Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clinical Pharmacology and Therapeutics, 52:561-568.
  15. Srinivas NR and Igwemezie LN (1992) Chiral separation by high pressure liquid chromatography. I: Review on indirect separation of enantiomers as diastereomeric derivatives using ultraviolet, fluorescence and electrochemical detection. Biomedical Chromatography, 6:163-167.
  16. Srinivas NR, Hubbard JW, Korchinski ED and Midha KK (1993) Enantioselective pharmaco-kinetics of dl-threo-methylphenidate in humans. Pharmaceutical Research, 10:14-21.
  17. Srinivas NR (1994) A note on chromatographic analysis of enantiomers by indirect method. Biomedical Chromatography, 8:52.
  18. Srinivas NR (1994) A need for an uniform approach for indexing data of the stereoisomers. Biomedical Chromatography 8:151.
  19. Srinivas NR, Shyu WC, Upmalis D and Barbhaiya RH (1995) Lack of pharmacokinetic interaction between transnasal butorphanol and sumatriptan. Journal of Clinical Pharmacology, 35:432-437.
  20. Srinivas NR, Shyu W and Barbhaiya RH (1995) Gas chromatographic separation of enantiomers as diasteromers following pre-column derivatization and applications to pharmacokinetic studies: A review. Biomedical Chromatography, 9:1-9.
  21. Srinivas NR, Shyu WC, Shah VR, Campbell DA and Barbhaiya RH (1995) High-performance liquid chromatographic assay for the quantitation of nadolol in human plasma using fluorescence detection. Biomedical Chromatography, 9:75-79.
  22. Thompson DS, Greco FA, Miller AA, Srinivas NR, Igwemezie LN, Hainsworth JD, Schacter LP, Kaul S, Barbhaiya RH, Garrow GC, and Hande KR. (1995) A phase I study of etoposide phosphate administered as a daily 30 minute infusion for 5 days. Clinical Pharmacology and Therapeutics, 57:499-507.
  23. Belas FA, Phillips MA, Srinivas NR, Barbhaiya RH and Blair IA. (1995) Simultaneous determination of nadolol enantiomers in human plasma by high performance liquid chromatography using fluorescence detection. Biomedical Chromatography, 9:145-149.
  24. Brooks DJ, Srinivas NR, Alberts DS, Thomas T, Igwemezie LN, McKinney LM, Randolph J, Schacter L, Kaul S and Barbhaiya RH. (1995). Phase I and pharmacokinetic study of etoposide phosphate. Anti-Cancer Drugs, 6:637-644.
  25. Srinivas NR, Shyu WC, Shah VR, Campbell DA and Barbhaiya RH. (1995) Stereoselective analysis of nadolol in human plasma. Biomedical Chromatography, 9:226-228.
  26. Srinivas NR, Shyu WC, Weiner RS, Tay LK, Greene DS, and Barbhaiya RH (1995) Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice. Journal of Pharmaceutical Sciences, 84:1488-1489.
  27. Warner GL, Johanson L, Gonchoroff D, Weiner R, Shyu W, Srinivas N, Linsley P, Cabiran K, and Davidson T (1995) CTLA4Ig inhibits a T-cell dependent antibody response in Cynomolgus monkeys. Journal of Cell Biochemistry, 21A:86.
  28. Stancato FA, Srinivas NR and Knupp CA (1996) Effect of temperature on the high-performance liquid chromatographic separation of the anti-HIV agents, didanosine and stavudine. Biomedical Chromatography, 10:29-31.
  29. Srinivas NR, Knupp CA, Batteiger B, Smith RA and Barbhaiya RH (1996) A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulfamethoxazole in HIV seropositive asymptomatic male patients. British Journal of Clinical Pharmacology, 41:207-215.
  30. Srinivas NR, Weiner RS, Warner G, Shyu WC, Davidson T, Fadrowski CF, Tay LK, Lee JS, Greene DS and Barbhaiya RH (1996) Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. Journal of Pharmaceutical Sciences, 85:1-4.
  31. Srinivas NR, Barr WH, Shyu WC, Mohandoss E, Chow S, Staggers J, Balan G, Belas FJ, Blair IA and Barbhaiya RH (1996) Bioequivalence of two tablet formulations of nadolol using single and multiple dose data: Assessment using stereospecific and non-stereospecific assays. Journal of Pharmaceutical Sciences, 85:299-303.
  32. Srinivas NR, Weiner RS, Shyu WC, Calore JD, Tritschler D, Tay LK, Lee JS, Greene DS and Barbhaiya RH (1996) A pharmacokinetic study of intravenous CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in mice. Journal of Pharmaceutical Sciences, 85:296-298.
  33. Campbell DA, Shah VR, Srinivas NR, and Shyu WC (1996) High-performance liquid chromatographic analysis of 2′-fluoro-2′,3′-dideoxyadenosine and 2′-fluoro-2′,3′-dideoxyinosine in dog plasma and urine. Journal of Pharmaceutical Sciences, 85: 890-892.
  34. Shah VR, Srinivas NR, Campbell DA,. Mantha S, Duncan G, Schuster A, Whigan DW and Shyu WC (1996) High-performance liquid chromatographic-ultraviolet assay for the simultaneous quantitation of BMS-181101 and its putative metabolites in rat and monkey plasma. Biomedical Chromatography, 10:135-138.
  35. Kaul S, Srinivas NR, Igwemezie LN and Barbhaiya RH (1996) A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in treatment of cancer patients. Seminars in Oncology, 23 (Supplement 13): 15-22.
  36. Kaul S, Srinivas NR, Mummaneni V, Igwemezie LN and Barbhaiya RH (1996) Evaluation of the effects of gender, age, and race on the pharmacokinetics of etoposide following intravenous administration of etoposide phosphate in cancer patients. Seminars in Oncology, 23 (Supplement 13): 23-29.
  37. Weiner RS, Srinivas NR, Calore JD, Fadrowski CG, Shyu WC and Tay LK (1997) A sensitive enzyme immunoassay for the quantitation of human CTLA4Ig fusion protein in mouse serum: Pharmacokinetic application to optimizing cell line selection. Journal of Pharmaceutical and Biomedical Analysis, 15: 571-579.
  38. Srinivas NR, Shyu WC, Lee JS, Greene DS, and Barbhaiya RH (1997) Lack of food effect on the steady state pharmacokinetics of BMS-181101 in humans. Biopharmaceutics and Drug Disposition 18: 585-593.
  39. Srinivas NR, Shah VR, Papp EA and Shyu WC (1997) A simple high-performance liquid chromatographic assay with ultraviolet detection for the determination of a monobactam antibiotic. Journal of Liquid Chromatography and Related Technology 20: 1091-1101.
  40. Shyu WC, Srinivas NR, Weiner RS, Warner G, Gleason C, Tay LK, Greene DS, and Barbhaiya RH (1997) Pharmacokinetics of CTLA4Ig (BMS-188667), an immunosuppressive agent, following single and multiple doses in monkeys. Pharmaceutical Sciences 2: 597-600.
  41. Srinivas NR, Shyu WC, Weiner RS, Warner G, Comereski C, Tay LK, Greene DS and Barbhaiya RH (1997) Assessment of dose proportionality, absolute bioavailability, and antigenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. Pharmaceutical Research, 14: 911-916.
  42. Srinivas NR, Shyu WC, Gleason C, Greene DS, and Barbhaiya RH (1997) Effects of age, gender, and diurnal variation on the steady state pharmacokinetics of BMS-181101, an anti-depressive agent, in humans. Clinical Pharmacology and Therapeutics 62: 408-416.
  43. Srinivas NR (1997) Review of chiral liquid chromatographic methods for the separation of racemic drugs: examples of stereoselectivity in pharmacology and pharmacokinetics of racemates. In Recent Trends in Pharmaceutical Sciences [Editors: Drs. G. Jagadeesh, Suresh Babu, K.P. Ravindra], published by: Alumni of American Association of Government College of Pharmacy.
  44. Srinivas NR and Kaul S (1998) Pharmacokinetics of a nootropic agent, BMY-21502, and its metabolites in dogs. European Journal of Drug Metabolism and Pharmacokinetics 23: 61-65.
  45. Srinivas NR, Shah VR, Schuster A, Whigan D, and Shyu WC (1998) High performance liquid chromatographic-electrochemical assay for the quantitation of BMS-181885 in monkey plasma. Journal of Chromatography B 705: 315-322.
  46. Srinivas NR, Weiner RS, Berry K, Tay LK, and Shyu WC (1998) Pharmacokinetics and pharmacodynamics of CTLA4Ig, a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice. Pharmacy and Pharmacology Communications, 4: 1-7.
  47. Srinivas NR (1998) Selection of internal standard for quantitative analysis of enantiomers following precolumn chiral derivatization. Journal of Chromatography B 709: 321-323. 48. Yao M, Shah VR, Shyu WC, and Srinivas NR (1998) A sensitive liquid chromatographic mass spectrometric determination of nefazodone and its metabolites, hydroxynefazodone, m-chlorophenyl piperazine, and triazole-dione, in human plasma using single ion monitoring. Journal of Chromatography B 718:77-85.
  48. Srinivas NR, Shyu WC, Soong CW, and Greene DS (1998) Absolute bioavailability and dose proportionality of BMS-181885, an anti-migraine agent, following the administration of single intravenous doses to Cynomolgus monkeys. Journal of Pharmaceutical Sciences, 87:1170-1172.
  49. Srinivas NR (1999) Clinical pharmacy education in India – a view point. Indian Journal of Pharmaceutical Education 33, 8-9.
  50. Chang SY, Whigan D, Shyu WC, and Srinivas NR (1999) Sensitive triple quad mass spectrometric assay for the determination of BMS-181885, a novel 5-HT1 agonist, in human plasma using solid phase extraction. Biomedical Chromatography, 13: 425-430.
  51. Schulze GE, Proctor JM, Dominick MA, Flint OP, Srinivas NR, and B.E. Schilling BE (1999) Intranasal toxicity of BMS-181885, a novel 5-HT1 agonist. International Journal of Toxicology, 18: 285-296.
  52. Srinivas NR, Shyu WC, Ferreira I, Chang S, Mangold B, Greene DS, and Barbhaiya RH (1999) Safety, dose proportionality, and bioavailability of BMS-181885, a 5-HT1 agonist, following intranasal and intravenous administration to humans. Journal of Applied Therapeutic Research, 2:243-251.
  53. Srinivas NR and Shyu WC (1999) Single and multiple dose pharmacokinetics of 2′-fluoro-2′,3′-dideoxyadenosine and 2′-fluoro-2′,3′-dideoxyinosine, anti-HIV agents, in rats. European Journal of Drug Metabolism and Pharmacokinetics, 24:329-334, 1999.
  54. Yao M and Srinivas NR (2000) Simultaneous quantitation of d7-nefazodone, nefazodone, d7-hydroxynefazodone, hydroxynefazodone, m-chlorophenyl piperazine, and triazole dione in human plasma by liquid chromatographic mass spectrometry. 14:106-112.
  55. Frantz SW, Srinivas NR, Dominick M, Kelley W, Sanderson T, and Schilling B (2000) Safety assessment of BMS-204352, a novel therapeutic agent for the treatment of acute stroke. European Journal of Neurology, 7(suppl): Abstract P3017.
  56. Krishna R, Srinivas NR, Yao M, Kaul S, Meeker JB, Gold M, Uderman H, and Knupp CA (2000) Assessment of diurnal variation and intra-subject variability of nefazodone and its metabolites at steady state in healthy subjects following morning and evening dosing of an extended release formulation. AAPS PharmSci 2 (2): Abstract 612.
  57. Fayad P, Caplik J, Culligan N, K Edwards, Maisel J, Moonis M, Newman G, Srinivas NR, Wirkowski E and Bozik M (2000) Safety, tolerability and pharmacokinetics of intravenous BMS-204352, a novel maxi-K channel opener , in patients up to 48 hours after acute ischemia stroke, European Journal of Neurology, 7(suppl): Abstract SC-30.
  58. Srinivas NR, Shyu WC, Greene DS, and Barbhaiya RH (2001) Oral absorption of BMS-181101, an anti-depressant, from the various gastrointestinal regions of healthy human subjects. Journal of Applied Therapeutic Research. 3: 7-18.
  59. Yao M, Chen L, and Srinivas NR (2001) Quantitative determination of itraconazole in rat plasma using liquid chromatography mass spectrometry Journal of Chromatography B, 752:9-16.
  60. Srinivas NR, Barbhaiya RH, and Midha KK (2001) Enantiomeric drug development: Issues, considerations, and regulatory requirements. Journal of Pharmaceutical Sciences, 90:1205-1215.
  61. Gribkoff VK, Starrett JE, Dworetzky SL, Hewasasam P, Boissard CG, Frantz SW, Hibbard JR, Huston K, Johnson G, Krishnan BS, Kinney GG, Lombardo LA, Meanwell NA, Molinoff PB, Myers RA, Moon SL, Ortiz A, Pajor L, Pieschl RL, Post-Munson DJ, Signor LJ, Srinivas N, Taber MT, Thalody G, Trojnacki JT, Wiener H, Yeleswaram K, and Yeola SW (2000) Targeting acute ischemic stroke with calcium sensitive opener of Maxi-K potassium channels. Nature Medicine, 7:471-477.
  62. Krishna R, Yao M, Kaczor D, Vachharajani N, and Srinivas NR (2001) In vitro protein studies of BMS-204352: lack of protein binding displacement interaction in human serum. Biopharmaceutics and Drug Disposition 22, 41-44.
  63. Srinivas NR (2001) Impact of chirality: A look in the mirror from a pharmacokinetic perspective. Invited Review. Indian Journal of Pharmaceutical Sciences (in press).
  64. Yao M, Mantha S, Shah VR, Vachharajani N, Arnold M, Pursley J, and Srinivas NR (2002) A sensitive quantitative liquid chromatographic mass spectrometric method for BMS-204352 in dog plasma. Biomedical Chromatography, 16(3):175-182.
  65. Krishna R, Yao M, Srinivas NR, Shah V, Pursley JM, Arnold M, and Vachharajani NN (2002) Disposition of radiolabeled BMS-204352 in rats and dogs. Biopharmaceutics and Drug Disposition, 23(1):41-46.
  66. Krishna R, Shah VR, Mantha S, Vachharajani NN, and Srinivas NR (2002) Pharmacokinetics and dose proportionality of BMS-204352 after intravenous administration to dogs. Biopharmaceutics and Drug Disposition, 23:83-86.
  67. Kiesewetter DO, Jagoda EM, Starrett JR, Gribkoff VK, Hewasasam P, Srinivas NR, Salazar D, and Eckelman WC (2002) Radiochemical synthesis and biodistribution of a novel maxi-K potassium channel opener. Nuclear Medicine and Biology, 29 (1):55-59.
  68. Krishna R, Palme H, Zeng J, and Srinivas NR (2002) Effect of dose and input rate on the brain penetration of BMS-204352 following intravenous administration to rats. Biopharmaceutics and Drug Disposition, 23: 227-231.
  69. Krishna R, Shah V, and Srinivas NR (2002) Pharmacokinetics and dose proportionality of BMS-204352 after intra-arterial administration to rats. Biopharmaceutics and Drug Disposition, 23: 233-237.
  70. Mamidi RNVS, Mullangi R, Katneni K, Ravikanth B, Babu A, Rani U, Naidu MUR, Srinivas NR, and Rajagopalan R (2002) Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. Journal of Clinical Pharmacology, 42:670-675.
  71. Mamidi RNVS, Mullangi R, Kota J, Bhamidipati R, Khan AA, Katneni K, Datla S, Singh SK, Koteshwar Rao Y, Seshagiri Rao C, Srinivas NR, and Rajagopalan R (2002) Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats. Journal of Biopharmaceutics and Drug Disposition 23: 273-282.
  72. Ramesh M, Yao M, and Srinivas NR (2003) Resolution and quantitation of enantiomers of ketoprofen by liquid chromatography: A review. Biomedical Chromatography, 17: 423-434.
  73. Upreti VV, Mamidi RNVS, Katneni K, and Srinivas NR (2003) Quantitative determination of DRF-1042 in human plasma by HPLC: Validation and application in clinical pharmacokinetics. Biomedical Chromatography, 17: 385-390.
  74. Ramesh M, Mamidi NVS, Jagannath K, Singh SK, Koteshwar Rao Y, Seshagiri Rao C, Rajagopalan R, and Srinivas NR (2003) Oral bioavailability and pharmacokinetics of DRF-4367, a new cox-2 inhibitor in rats. European Journal of Drug Metabolism and Pharmacokinetics 28: 137-141.
  75. Srinivas NR and Mamidi RNVS (2003) Bioanalytical considerations for compounds containing free sulfhydryl (SH) groups. Biomedical Chromatography 17, 285-291.
  76. Mamidi RNVS, Benjamin B, Khan AA, Muzeeb S, Mullangi R, and Srinivas NR (2003) Open access generic method for continuous determination of major human cytochromeP450 probe substrates/metabolites and application in in vitro drug metabolism studies. Xenobiotica 33: 1233-1245.
  77. Mamidi RNVS, Benjamin B, Ramesh M, and Srinivas NR (2003) Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. Biomedical Chromatography, 17: 417-421.
  78. Jagannath K, Chaluvadi MR, Mullangi R, Mamidi RNVS, and Srinivas NR (2004) Intravenous pharmacokinetics, oral bioavailability, and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats. Biopharmaceutics and Drug Disposition, 25:323-328.
  79. Chatterjee A, Digumarti R, Mamidi RNVS, Katneni K, Upreti VV, Surath A, Uppalapati S, Jiwatani S, Subramaniam S and NR Srinivas (2004) Safety, pharmacokinetics, and pharmaco-dynamics of an orally active novel campthothecin analog, DRF-1042, in patients with refractory solid tumors in a phase I dose escalation study. Journal of Clinical Pharmacology, 44: 723-736.
  80. Srinivas NR (2004) Evaluation of experimental strategies for the development of chiral chromatographic methods based on diasteromer formation. Biomedical Chromatography, 18: 207-233.
  81. Srinivas NR (2004) Role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus? Journal of Clinical Pharmacology 44: 115-119.
  82. Mullangi R, Raja Reddy K, Ravikanth B, Mamidi RNVS, and Srinivas NR (2004) HPLC method for determination of DRF-4367 in rat plasma: validation and its application to pharmacokinetics in Wistar rats. Biomedical Chromatography, 18:576-580.
  83. Ravikanth B, Dravid P, Mullangi R, and Srinivas NR (2004) Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: Applicability for the development of novel oxazolidinones. Xenobiotica 34: 571-579.
  84. Mustafa S, Trivedi RK, Mamidi RNVS, Mullangi R, and Srinivas NR (2004) Development of a validated chiral high-performance liquid chromatographic method to evaluate the in vivo enantiomeric inversion of DRF 2725. Journal of Chromatography B 809: 23-30.
  85. Trivedi RK, Mamidi RNVS, Mullangi R and Srinivas NR (2004) LC-MS/MS method for quantitative determination of lipoic acid in rat plasma: validation and its application to pharmacokinetics in Wistar rats. Biomedical Chromatography, 18: 681-686.
  86. Srinivas NR (2004) Clinical implications and applications of grapefruit juice intake during oral therapy of drugs known to be metabolized by cytochrome P450 3A4 isozyme. Indian Journal of Pharmaceutical Sciences 66(5): 602-606.
  87. Zeng J, Palme H, Srinivas N and Arnold M (2004). Determination of a neuroprotective agent (S)-(+)-BMS-204352 in human, rat, and dog plasma by enantioselective liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, 811:109-117.
  88. Srinivas NR. (2004). Clinical pharmacokinetic data of racemic drugs obtained by indirect method following precolumn diasteromer formation: Is the influence of racemization during chiral derivatization significant? Biomedical Chromatography 18: 343-349.
  89. Srinivas NR (2004) Simultaneous chiral analyses of multiple analytes: case studies, implications and developmental considerations. Biomedical Chromatography, 18:759-784.
  90. Zhang D, Wang L, Krishna R, Zeng J, Mitroka J, Narasimhan N, Reeves RA, Srinivas NR, and Klunk LJ (2005) Metabolism and pharmacokinetics of radiolabeled Maxipost in healthy subjects: A case study of protein covalent binding imposing little impact on developability of a drug for stroke. Drug Metabolism and Disposition 33:83-93.
  91. Dravid PV, Bhamidipati RK, Ramesh M, and Srinivas NR (2005) Validation of a simple bioanalytical method for determination of DRF-6196, a novel oxazolidinone in mouse plasma: application to a single dose pharmacokinetic study. Arzneimittel Forschung Drug Research 55:239-244.
  92. Chatterjee A, Digumarti R, Mamidi RNVS, Katneni K, Upreti VV, Surath A, Uppalapati S, Jiwatani S, and Srinivas NR (2005) Safety, tolerability and pharmacokinetics of a capsule formulation of DRF-1042, a novel campthothecin analog, in refractory cancer patients in a bridging Phase I clinical study. Journal of Clinical Pharmacology 45:453-460.
  93. Bhamidipati R, Dravid PV, Muzeeb S, Khan AA, Singh SK, Rao YK, Mullangi R, and Srinivas NR (2005) Preclinical assessment of DRF 4367, a novel Cox-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative interspecies in vitro metabolism. Xenobiotica 35:253-271.
  94. Shantha Kumar R, Chawla S, Nachaegari SK, Singh SK, and Srinivas NR (2005) Validated HPLC analytical method with programmed wavelength UV detection for simultaneous determination of DRF-4367 and phenol red in rat in situ intestinal perfusion study. Journal of Pharmaceutical and Biomedical Analysis 38:173-179.
  95. Bhamidipati RK, Ramesh M, and Srinivas NR (2005) Bioanalytical aspects in characterization and quantification of glucuronide conjugates of xenobiotics in various biological matrices. Current Pharmaceutical Analysis 1(3):251-264.
  96. Trivedi RK, Raja Reddy K, Ramesh M, and NR Srinivas NR (2005) Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: Assay development, validation and application to a clinical study. Journal of Pharmaceutical and Biomedical Analysis 39:661-669.
  97. Bhamidipati R, Venkatesh P, Dravid PV, Narasimhulu CP, Das J, Mullangi R, and Srinivas NR (2005) Assessment of oral bioavailability, and preclinical pharmacokinetics of DRF 6196, a novel oxazolidinone analogue, in comparison to mice. European Journal of Drug Metabolism and Pharmacokinetics: 30:187-193.
  98. Muzeeb S, Pasha MK, Basha SJS, Ramesh M, and Srinivas NR (2005) Effect of 1-aminobenzotriazole on the in vitro metabolism and pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate, in Wistar rats. Xenobiotica 35:825-838.
  99. Pavan Kumar V, Vinu MC, Ramani AV, Mullangi R, and Srinivas NR (2006) Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. Biomedical Chromatography 20:125-132.
  100. Pasha MK, Basha SJ, Sashikumar D, Mullangi R, and Srinivas NR (2006) Analysis of five HMG-CoA reductase inhibitors- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. Biomedical Chromatography 20:282-293.
  101. Chawla S, Ghosh S, Sihorkar V, Nellore R, Kumar TR, and Srinivas NR (2006) High-performance liquid chromatography method development and validation for simultaneous determination of five model compounds, antipyrine, metoprolol, ketoprofen, furosemide and phenol red, as a tool for the standardization of rat in situ intestinal permeability studies using timed wavelength detection. Biomedical Chromatography 20:349-357.
  102. Srinivas NR. (2006). Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomedical Chromatography 20:383-414.
  103. Kumar TR, Shitut NR, Kumar PK, Vinu MC, Kumar VV, Mullangi R, and Srinivas NR (2006) Determination of rosuvastatin in rat plasma by HPLC: validation and its application to pharmacokinetic studies. Biomedical Chromatography 20:881-887.
  104. Yao M and Srinivas NR (2006) Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma. Biomedical Chromatography 20:1017-1023.
  105. Venkatesh P, Harisudhan T, Choudhury H, Mullangi R and Srinivas NR (2006) Simultaneous estimation of six anti-diabetic drugs-glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay. Biomedical Chromatography 20:1043-1048.
  106. Basavaraj, Shantha Kumar TR, Sundaramurthi P, Sihorkar V, Venkatesh P, Ramesh M, Singh SK, and Srinivas NR (2006) Complexation of poorly soluble new chemical entity with hydroxypropyl-beta-cyclodextrin: Selection of ternary component to improve dissolution and bioavailability. Pharmaceutical Development Technology 11:443-451.
  107. Nirmala C, Trivedi R, Prasanthi PV, Mullangi R, and Srinivas NR (2006) Simultaneous estimation of six anti-diabetic drugs-glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay. Biomedical Chromatography 20:945-950.
  108. Venkatesh P, Harisudhan T, Choudhury H, Mustafa S, Pasha MK, Mullangi R, and Srinivas NR (2007) Pharmacokinetics of etoposide in rats with acute renal failure (ARF) induced by uranyl nitrate – optimization of time required to induce ARF by uranyl nitrate using pharmacokinetics as a surrogate. European Journal of Drug Metabolism and Pharmacokinetics 32:189-196.
  109. Srinivas NR (2006) Drug disposition of chiral and achiral drug substrates metabolized by cytochrome P450 2D6 isozyme: Case studies, analytical perspectives and developmental implications. Biomedical Chromatography 20:466-491.
  110. Ramesh M and Srinivas NR (2006) Validation of a simple HPLC method for DRF-4848, a novel COX-2 inhibitor suitable for pharmacokinetic application in rats. Biomedical Chromatography 20:1289-1294.
  111. Ramesh M, Jagannath K, Bhamidipati R, Padakanti S, Pal M, and Srinivas NR (2006) Pharmacokinetic studies of DRF-4848, a novel COX-2 inhibitor, in rats: Assessment of oral bioavailability, dose proportionality, formulation and food effects. Asian Journal of Drug Metabolism and Pharmacokinetics (in press).
  112. Mustafa S, Venkatesh P, Pasha K, Mullangi R, and Srinivas NR (2006) Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate – do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF? Xenobiotica 36:1239-1258.
  113. Vittal S, Shitut NR, Ranjit Kumar T, Vinu MCA, Mullangi R, and Srinivas NR (2006) Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. Biomedical Chromatography 20:1252-1259.
  114. Pavan Kumar VV, Vinu MC, Mullangi R, and Srinivas NR (2007) Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel PPAR dual activator. European Journal of Drug Metabolism and Pharmacokinetics 32(1):29-37.
  115. Muzeeb S, Venkatesh P, Mullangi R, and Srinivas NR (2006) Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: Impact on oral bioavailability, absorption and metabolic disposition in rats. Xenobiotica 36:838-856.
  116. Yao M, Swaminathan A, and Srinivas NR (2006) Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology. Biopharmaceutics and Drug Disposition 28:35-42.
  117. Muzeeb S, Basha SJS, Shashikumar D, Mullangi R, and Srinivas NR (2006) Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferase (UGT): Role of UGT1A1, 1A3 and 1A8. European Journal of Drug Metabolism and Pharmacokinetics 31:299-309.
  118. Basha SJS, Naveed SA, Tiwari NB, Shashikumar D, Muzeeb S, Ranjith Kumar T, Vijaya Kumar N, Prabhakar Rao N, Srinivas N, Mullangi R, and Srinivas NR (2007) Concurrent determination of ezetimibe and its phase-I and II metabolites by HPLC with UV detection: Quantitative application to various in vitro metabolic stability studies and for qualitative estimation in bile. Journal of Chromatography B Analytical Technology and Biomedical Life Sciences 853(1-2): 88 – 96.
  119. Trivedi RK, Dubey PK, Mullangi R, and Srinivas NR (2007) Development and validation of enantioselective HPLC-UV method on Chiralpak AD-H to quantify (+)- and (-)-torcetrapib enantiomers in human plasma: application to a pharmacokinetic study. Journal of Chromatography B 857:224-230.
  120. Srinivas NR Changing need of bioanalysis during drug development (2008). Biomedical Chromatography 22(3):235-243.
  121. Raja Reddy K, Karthik A, Chakradhar L, Mullangi R, and Srinivas NR (2007) Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in a small volume human plasma samples and its application to a clinical study. Arzneimittel-Forschung (Drug Research) 57:705-711.
  122. Trivedi RK, Layek B, Santosh Kumar T, Vittal S, Ganneboina R, Dubey PK, Mullangi R, and Srinivas NR (2007) Chiral bioanalysis of torcetrapib enantiomers in hamster plasma by normal-phase liquid chromatography and detection by atmospheric pressure ionization tandem mass spectrometry. Journal of Chromatography B 860:227-234.
  123. Trivedi RK, Dubey PK, Mullangi R, and Srinivas NR (2007) Development and validation of a sensitive LC-MS/MS method with electrospray ionization using multiple ions for quantitation of torcetrapib in hamster and dog plasma. Biomedical Chromatography 22(3):316-326.
  124. Layek B, Santosh Kumar T, Trivedi RK, Mullangi R, and Srinivas NR (2008) Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of rhein in human plasma: application to a pharmacokinetic study. Biomedical Chromatography 22(6): 616 – 624.
  125. Polepally AR, Pavan Kumar VV, Bhamidipati R, Kota J, Naveed SA, Reddy KH, Mamidi RNVS, Selvakumar N, Mullangi R, and Srinivas NR (2008). Assessing the issue of instability due to Michael adduct formation in novel chemical entities possessing a carbon-carbon double bond during early drug development – Applicability of common laboratory analytical protocols. Biomedical Chromatography, 22(9): 960 – 976.
  126. Srinivas NR (2008). Methodology of internal standard selection – Comment on the work of Wang and co-workers: Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. Biomedical Chromatography 22(10):1180.
  127. Srinivas NR (2008) Assessment of bioequivalence of drug racemates: What are the cues from a bioanalytical perspective – Stereoselective vs. Nonstereoselective? Biomedical Chromatography 22(11): 1318 – 1320.
  128. Srinivas NR (2008) Clinical use of St. John’s Wort: Drug-drug interaction potential of marketed products and challenges for drug development. Asian Journal of Pharmacodynamics and Pharmacokinetics 8(2):109-126.
  129. Srinivas NR (2008) Applicability of nonlinear calibration regression for quantitative determination of parent and metabolite(s) in bioequivalence assessment. Biomedical Chromatography 22: 1315-1317.
  130. Srinivas NR (2008) Dual drug interactions via P-glycoprotein (P-gp) / cytochrome P450 (CYP3A4) interplay: Recent case study between oral atorvastatin and verapamil. European Journal of Clinical Pharmacology, 64(11): 1135 – 1136.
  131. Mullangi R, Agarwal S, and Srinivas NR (2009) Measurement of xenobiotics in saliva: Is saliva an attractive alternative matrix? Case studies and analytical perspectives. Biomedical Chromatography, 23: 3-25.
  132. Srinivas NR (2009) New Thinking in the Development of Novel Derivatization Reagents for Liquid Chromatography – Mass Spectrometric Detection. Biomedical Chromatography 23(1): 107 – 108.
  133. Srinivas NR (2008) Single dose pharmacokinetic interaction between artesunate and amodiaquine: assembling the clues for the ‘purported’ interaction. European Journal of Clinical Pharmacology, 64: 1231-1233.
  134. Ahlawat P and Srinivas NR (2008) Interspecies scaling of a campthothecin analogue: Human predictions for intravenous topotecan using animal data. Xenobiotica 38: 1235-1247.
  135. Srinivas NR (2008) Reversal in elution order in liquid chromatography – compilation of experimental observations. Biomedical Chromatography 23: 222-223.
  136. Mullangi R and Srinivas NR (2008) Clopidogrel: Review of bioanalytical methods for clinical applications, pharmacokinetics/pharmacodynamics overview, and update on recent trends in drug-drug interaction studies. Biomedical Chromatography 23:26-41.
  137. Srinivas NR (2008) Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon? Biomedical Chromatography, 23(4): 447 – 449.
  138. Srinivas NR (2008) The drug-drug interaction potential of rifampicin. Clinical Therapeutics 30: 1932-1933.
  139. Ahlawat P and Srinivas NR (2008) Allometric prediction of the human pharmacokinetic parameters for naveglitazar. European Journal of Drug Metabolism and Pharmacokinetics. 33(3): 187-190.
  140. Srinivas NR (2009) Pharmacokinetic screening strategy for discovery work – use of rodent species: lessons learnt and probing newer thoughts. Drug Metabolism and Pharmacokinetics, 24(2): 97 – 198.
  141. Srinivas NR (2009) Structurally modified ‘dietary flavonoids’ – are these viable drug candidates for chemoprevention? Current Clinical Pharmacology, 4: 67-70.
  142. Srinivas NR (2009) Dodging matrix effects in liquid chromatography tandem mass spectrometric assays – compilation of key learnings and perspectives. Biomedical Chromatography, 23(5): 451 – 454.
  143. Ahlawat P and Srinivas NR (2009) Allometric scaling of a metabolically complex campthothecin analog: differences in scaling of irinotecan and its active metabolite, SN-38. Arzneimittel Forschung Drug Research, 59(6): 311 – 317.
  144. Srinivas NR (2009) The emerging technique, micro extraction in packed syringes (MEPS) – Can it eliminate matrix effects and fit with LC/MS/MS strategy? Journal of Separation Science, 32: 165-166.
  145. Srinivas NR (2009) Novel 6-hydroxy chroman based derivatization reagent for HPLC-EC: Challenges of ‘unsuspected’ chirality. Biomedical Chromatography 23(6): 672 – 673.
  146. Srinivas NR and Ramesh M (2009) Digoxin – a therapeutic agent and mechanistic probe: Review of liquid chromatographic mass spectrometric methods and recent nuances in the clinical pharmacology attributes of digoxin. Bioanalysis 1(1):97-113.
  147. Srinivas NR and Lim CK (2009) Enhancement of the impact of manuscript submissions to BMC – Editorial perspectives. Biomedical Chromatography, 23: 1-2.
  148. Srinivas NR (2009). Editorial – Bioanalysis: First-in human assays – excitement and introspection. Bioanalysis 1(2):263-4.
  149. Srinivas NR (2009) Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments: Overview of the recent trends. Arzneimittel Forschung Drug Research, 59(4): 155 – 165.
  150. Srinivas NR (2008) Applicability of LC/MS/MS assay for 6-methoxy-2-napthylacetic acid to support the bioequivalence study of nabumetone – Comments on the research work of Patel et al (2008). Biomedical Chromatography 23(6): 1213 – 1214.
  151. Srinivas NR, Trivedi R, and Mullangi R (2009) A review of bioanalysis of torcetrapib for animal and human pharmacokinetic studies – Applicability of chiral and achiral methodologies. Bioanalysis (1(3):619-28.
  152. Srinivas NR (2009) Unsuspected and Paradoxical Drug Interaction Potential with Rifampicin – Things to Ponder with Antiretroviral Therapy. Journal of Infectious Disease, 199: 766-767.
  153. Srinivas NR (2009) Is there a place for drug combination strategies using clinical pharmacology attributes? – Review of current trends in research. Current Clinical Pharmacology, 4(3): 220 – 228.
  154. Srinivas NR (2009) Suspected differential interaction of digoxin with imidafenacin and propantheline – Some thoughts for introspection. Drug Metabolism and Pharmacokinetics, 24(2) 194 – 196.
  155. Srinivas NR, Ahlawat P, Trivedi R, and Mullangi R (2009) Use of bile correction factors for allometric prediction of human pharmacokinetic parameters of torcetrapib, a facile cholesteryl ester transfer protein inhibitor. European Journal of Drug Metabolism and Pharmacokinetics, 34(1): 57 – 63.
  156. Yao M and Srinivas NR (2009) Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: Overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives. Biomedical Chromatography, 23(7): 677 – 691.
  157. Srinivas NR (2009) Hyperthermic intraperitoneal perfusion chemotherapy – Views on the observed variability in oxaliplatin pharmacokinetics. European Journal of Clinical Pharmacology, 65(3): 321 – 322.
  158. Srinivas NR (2009) Fast dissolving meloxicam formulation for acute dental pain – Thoughts to ponder. Asian Journal of Pharmaceutics 2(4): 183-184.
  159. Srinivas NR (2009) Dihydroartemisinin pharmacokinetics in patients with malaria after multiple doses – Assembling the clues and perspectives. Drug Metabolism and Pharmacokinetics, 24(3): 282 – 284.
  160. Srinivas NR (2008) Herbal drug usage with modern medicine 1: Case study of an enzyme inducer – Some perspectives. International Journal of Green Pharmacy, 2(4)188-193.
  161. Srinivas NR and Ahlawat P (2009) Prediction of human pharmacokinetic parameters for bicifadine, a non-narcotic analgesic, using animal data and principles of allometry. Arzneimittel Forschung Drug Research, 59(12):625-630.
  162. Srinivas NR (2009) Substrate specific pharmacokinetic interaction between endothelial receptor antagonists and phoshodiesterase-5 inhibitors – Assembling the clues. British Journal of Clinical Pharmacology, 67(4): 475 – 477.
  163. Srinivas NR (2009) Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain – Biopharmaceutic and pharmacokinetic challenges. European Journal of Drug Metabolism and Pharmacokinetics, 34(1): 7 – 10.
  164. Srinivas NR (2009) Sensitivity enhancement in tandem liquid chromatographic mass spectrometric assays by summation of two transition ion pairs – perspectives. Journal of Separation Science, 32: 483 – 486.
  165. Srinivas NR (2009) Formulation development for cancer compounds – biopharmaceutical issues and perspectives. Asian Journal of Pharmaceutics, 3(2): 90 – 94.
  166. Srinivas NR (2009) Stereoselective renal tubular secretion of cetirizine enantiomers – initial plasma and urine data analysis may hold the key. Fundamental Clinical Pharmacology 23(5): 537 – 538.
  167. Srinivas NR (2009) Drug-drug interaction studies in preclinical species – should metabolite(s) kinetics be studied? Xenobiotica, 39: 193 – 196.
  168. Pavan Kumar VV and Srinivas NR (2009) Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan from animal data. European Journal of Drug Metabolism and Pharmacokinetics, 33: 247 – 252.
  169. Srinivas NR (2009) CYP2C19 genotype based (R)-warfarin disposition assessment – some views on data analysis. Journal of Clinical Pharmacy and Therapeutics, 34(6):727-728.
  170. Srinivas NR (2009) Unsuspected polymorphic metabolism of ruptatidine via primary metabolite, desloratadine. Primary Care Respiratory Journal, 18(2):118-9.
  171. Srinivas NR (2009) Bioanalytical. 1– Revisit to assay validation parameters: stabilizing our stability programs. Biomedical Chromatography, 23(10): 1031 – 1033.
  172. Srinivas NR, Ahlawat P, and Basha SK (2009) Allometric modeling of ciclesonide, a non-halogenated glucocorticoid, and its active metabolite, desisobutyrylciclesonide, using animal derived pharmacokinetic parameters. American Journal of Therapeutics (in press).
  173. Srinivas NR (2009) Tigecycline and cyclosporine interaction – an interesting case of biliary excreted drug enhancing the oral bioavailability of cyclosporine. European Journal of Clinical Pharmacology, 65: 543 – 544.
  174. Srinivas NR (2009) Antacid use and reduced bioavailability of oral drugs: Case studies, overview and perspectives Arzneimittel Forschung Drug Research, 59(7): 327 – 334.
  175. Srinivas NR (2009) LC/MS/MS analysis of capsaicin using multiple transition pairs – Some viewpoints to ponder. Biomedical Chromatography, 23(10): 1129 – 1130.
  176. Mullangi R, Ahlawat P, and Srinivas NR (2010) Irinotecan and its active metabolite, SN-38: Review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomedical Chromatography, 24: 104 – 123.
  177. Kandasamy M, Tripathy K, Ravi S, Kamath N, Pai B, Srinivas NR, Kristjansson F, Thangam S (2010) Unsuspected poor metabolizer (PM) phenotypes of Fluoxetine in bioavailability/ bioequivalence studies from an Indian population perspective – Retrospective pharmacokinetic data evaluation. Arzneimittelforschung Drug Research, 60):12-21.
  178. Manjunath Swamy J, Kamath N, Radha Shekar AK, Srinivas NR, and Kristjansson F (2009) Sensitivity enhancement and matrix effect evaluation during summation of multiple transition pairs – case studies of clopidogrel and ramiprilat. Biomedical Chromatography, 24(5):528-534.
  179. Srinivas NR (2009) Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy – Does structural design, dosing and induction strategies have a role to play. European Journal of Drug Metabolism and Pharmacokinetics, 34(3-4): 147 – 150.
  180. Srinivas NR (2009) Eyeing opthalmic products: Bioequivalence assessment and drug development- Strategic considerations. Asian Journal of Pharmaceutics 3(2): 161 – 162.
  181. Srinivas NR (2009) Efflux transporter-mediated interactions with atorvastatin-interesting findings with multiple substrates: istradefylline, verapamil and rifampicin. Journal of Clinical Pharmacology, 49: 1492 – 1493.
  182. D’Souza HJ, Pai B, Kumar A, Srinivas NR, and Kristjansson F (2010) Influence of number of calibration standards within a defined range on pharmacokinetic disposition-case studies with omeprazole and clopidogrel carboxylic acid. Biomedical Chromatography, 24(5):544-549.
  183. Srinivas NR (2010) Time of celebration of decades of excellence. Biomedical Chromatography, 24: 1.
  184. Srinivas NR (2010) Is 1-methylxanthine an ideal model substrate for establishing the renal transport of organic ions? International Journal of Clinical Pharmacology and Therapeutics, 48(2):171-172.
  185. Srinivas NR (2010) Concept of fast dissolving formulations in acute treatment conditions – introspection, thoughts and perspectives. Asian Journal of Pharmaceutics, 4(1): 87 – 88.
  186. Srinivas NR (2010) Biopharmaceutics, formulations and exposure – editorial. Asian Journal of Pharmaceutics, 4(1) 1 – 3.
  187. Srinivas NR (2010) Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives. Arzneimittelforschung Drug Research, 60(12):731-748.
  188. Srinivas NR (2010) Baicalin, an emerging multi-therapeutic agent: Pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica, 40(5):357-367.
  189. Kandasamy M, Srinivas P, Subramaniam K, Ravi S, John J, Shekar R, Srinivas N, Thangam S (2010). Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes-focus on venlafaxine and O-desmethylvenlafaxine. European Journal of Clinical Pharmacology, 66(9):879-887.
  190. Sharma S, Mullangi R, Wade M, Gurav S, Sajja S, Shankar D, Srinivas N, Govindarajan R, Miller L, and Velleca M (2010) PK/PD models using a selective Ephrin B4 inhibitor JI-101 alone and in combination with other targeted agents and chemotherapy: Results of preclinical and ex-vivo studies. European Journal Cancer Supplements 8(7) 66.
  191. Gordon M, Sharma S, Miller L, Srinivas N, Sahu, R. Govindarajan, R. Mullangi, M. Velleca, D. Brittelli (2010) Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2, and PDGFRβ. European Journal Cancer Supplements 8(7) 127
  192. Mullangi R, Srinivas NR. (2011) Niacin and its metabolites: role of LC-MS/MS bioanalytical methods and update on clinical pharmacology. An overview. Biomedical Chromatography 25: 218–237.
  193. Gurav SD, Gilibili RR, Jeniffer S, Giri S, Srinivas NR, Mullangi R (2011) Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study. Biomedical Chromatography 25(7):794-800.
  194. Srinivas NR, Mullangi R (2011) An overview of various validated HPLC and LC-MS/MS methods for quantitation of drugs in bile: challenges and considerations. Biomedical Chromatography 25: 65 – 81.
  195. NR Srinivas (2011) Pharmacokinetics of tolbutamide in acute renal failure induced by glycerol – speculative thoughts and perspectives. Drug Metabolism and Pharmacokinetics 26(2):216-217.
  196. Gurav SD, Gilibili RR, Jeniffer S Zainuddin M, Giri S, Govindarajan R, Srinivas NR, Mullangi R. (2011) Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 – a novel triple kinase inhibitor in rats.. Arzneimittel Forschung 62(1):27-34.
  197. B Benjamin, Monashis S, Upendra B, Dhiraj A, and Srinivas NR (2012) The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds? Arzneimittel Forschung 62(4):194-201.
  198. Ravindranath Reddy Gibili, Mullangi R and Srinivas NR (2011) Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach. European Journal of Drug Metabolism and Pharmacokinetics 36(2):87-93.
  199. Srinivas NR (2011). Bioanalysis of complex clinical samples – considerations on analytical variability: Some thoughts to ponder. Biomedical Chromatography (6):734-736.
  200. Srinivas NR (2011) Stavudine delivery in an extended release formulation: Will it provide the right in vivo pharmacokinetics – Some key observations. Asian Journal of Pharmaceutics 5(1):52-53.
  201. Srinivas NR (2011). PK/PD modeling of rabeprazole in CYP2C19 genotypes: Consideration of the influence of thioether metabolite, CYP3A4, accumulation and CYP2D6 polymorphism may help to better develop and validate the model. European Journal of Clinical Pharmacology 67(9):965-966.
  202. Srinivas NR (2011). Evolving strategy on exploiting transporter mediated play for enhancing oral bioavailability and brain penetration – Case study of Idebenone. Journal of Pharmaceutical Scientific Research (in press).
  203. Srinivas NR (2011) Inclusion of black box warnings in the curriculum – A topic of global significance in patient care and management – Can the Journal and contributors do more? American Journal of Pharmaceutical Education;75(3):57a.
  204. Srinivas NR (2011) Clinical therapy with Immunosuppresants/Calcineurin inhibitors – Dilemma and challenges from a pharmacokinetic perspectives. Journal of Pharmaceutical Scientific Research 3 (3): 1093-1095.
  205. Srinivas NR (2011). Bridging pharmacokinetics between laboratory/veterinary animal species and man by allometry: A case study of intravenous tramadol. Journal of Pharmaceutical and Scientific Research 3(8) 1368-1372.
  206. Srinivas NR (2011). The rationality for using prodrug approach in drug discovery programs for new xenobiotics: Opportunities and challenges. European Journal of Drug Metabolism and Pharmacokinetics 36(2):49-59.211.
  207. Srinivas NR (2011) Incurred sample analysis: Dilemma in its applicability – should it be practiced for all bioanalytical assays involving single (parent or metabolite) or multiple analytes (parent/metabolite or parent with co-administered drugs)? Biomedical Chromatography 25(6):737-739.
  208. Srinivas NR (2011) Dealing with matrix effect: Should there be a cut off limit for signal ion suppression in quantitative assay validation?. Biomedical Chromatography 25(6):740-742.
  209. Gurav SD, Jeniffer S, Giri S, Srinivas NR, Mullangi R (2012). A strategy for extending the applicability of a validated plasma calibration curve to quantitative measurements in multiple tissue homogenates: A case study from a rat distribution study of JI-101, a triple kinase inhibitor. Biomedical Chromatography 26(4):419-424.
  210. Srinivas NR (2011) Blonaserin’s interesting food effect observations – Is lymphatic transport involved?. European Journal of Clinical Pharmacology 67(9):975-976.
  211. Srinivas NR (2011) Assessment of polymorphic metabolite data in bioavailability/ bioequivalence studies – considerations and challenges. Asian Journal of Pharmaceutics 5(3):157-161.
  212. Srinivas NR (2011) On the topic of bioavailability/bioequivalence- challenges with polymorphic metabolism. Editorial. Journal of Bioequivalence and Bioavailability 3(10): vii-viii
  213. Agarwal N, Sahu M, Abhyankar DJ, Werner TL, Benjamin B, Srinivas NR, Sharma S (2011) A drug–drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors. Journal Clinical Oncology 29: (suppl; abstr e15077).
  214. Srinivas NR (2012) Double or multiple/secondary peaks in pharmacokinetics: Considerations and challenges from a bioanalytical perspective. Biomedical Chromatography 26:407-408.
  215. Yao M, Srinivas NR (2012) Quantification of fexofenadine in biological matrices: a review of bioanalytical methods. Biomedical chromatography 26(8):942-961.
  216. Srinivas NR (2012) Buccal and intranasal lorazepam clinical pharmacokinetics: Is it adequate to compete with intravenous lorazepam in pediatric care patients? European Journal of Clinical Pharmacology 68(8):1221-1223.
  217. Mullangi R, Sharma K, Srinivas NR (2012) Review of HPLC methods and HPLC methods with mass spectrometric detection for direct determination of aspirin with its metabolite(s) in various biological matrices. Biomedical Chromatography 26(8):906-941.
  218. Srinivas NR (2013) Transdermal buprenorphine-interesting observations on the metabolite norbuprenorphine levels in elderly subjects. Eur J Clin Pharmacol. 69(8):1607-1608.
  219. Srinivas NR (2013). Is acetaminophen more prone to biliary excretion given orally than rectally in infants? Clinical Therapeutics 35(5):742-743.
  220. Srinivas NR (2013) The re-emergence of salting-out association with acetonitrile for modern day bioanalysis. Biomed Chromatography 27(5):545-547.
  221. Srinivas NR. (2013). Is pomegranate juice a potential perpetrator of clinical drug–drug interactions? Review of the in vitro, preclinical and clinical evidence. European Journal of Drug Metabolism and Pharmacokinetics 38(4):223-229.
  222. Mullangi R, Srinivas NR (2013) Review of the quantitative analysis of cholesteryl ester transfer protein inhibitors. Biomed Chromatogr. 27(10):1259-1272.
  223. Srinivas NR (2013) Commentary on: “study of the pharmacokinetic changes of tramadol in diabetic rats” is the handicapped renal pathway in DMIS contributing for the increased bioavailability of tramadol? Daru. Mar 15;21(1):23.
  224. Srinivas NR (2013) Do we have clarity on the therapeutic levels of morphine and its metabolites: Seeking answers for the dilemma? Journal of Pain & Palliative Care Pharmacotherapy. 27:163–166.
  225. Srinivas NR (2013) Review of grapefruit juice mediated drug-drug interactions – Trends from a chirality perspective. Journal of Applied Biopharmaceutics and Pharmacokinetics 1:45-55.
  226. Srinivas NR (2013) Cranberry juice ingestion and clinical drug-drug interaction potentials; Review of case studies and perspectives. Journal of Pharmacy and Pharmaceutical Sciences 16(2) 289 – 303.
  227. Srinivas NR, Mullangi R (2013) From Phase I to beyond – importance to switch to plasma from patients: Considerations and perspectives on bioanalytical procedures. Bioanalysis 5(18):2215-2218.
  228. Srinivas NR (2013) Do we have an understanding on incurred sample analyses – an introspection. Biomedical Chromatography 27(11):1367-1368.
  229. Srinivas NR (2014) Dilemma with matrix effect in bioanalysis – Perspectives from bioavailability/bioequivalent studies for product registration? Drug Research 64(6):335-336.
  230. Srinivas NR (2015) Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives. Eur J Drug Metab Pharmacokinet. 40(1):1-12.
  231. Sharma K, Suresh PS, Mullangi R, Srinivas NR (2015) Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors – review of assay methodologies and perspectives. Biomed Chromatogr. 29(6):803-834.
  232. Srinivas NR (2015) Biochanin A: Understanding the complexities in the paradoxical drug-drug interaction potential – A review. Eur J Drug Metab Pharmacokinetics. 40(2):119-125.
  233. Srinivas NR (2015) Acetaminophen absorption kinetics in altered gastric emptying – Establishing a relevant pharmacokinetic surrogate using published data. Journal of Pain and Palliative Care Pharmacotherapy 29:115–119.
  234. Srinivas NR (2016). Impact of Roux-en-Y gastric bypass surgery (RYGB) on pharmacokinetics of drugs: Implications and perspectives. American Journal of Therapeutics 23(6):e1826-e1838.
  235. Srinivas NR (2015) Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: Appraisal using peak concentration data. Biopharmaceutics and Drug Disposition 36(9):575-586.
  236. Srinivas NR (2016) Limited sampling strategy for the prediction of extent of absorption (AUC) of statins: Reliability of peak concentration (Cmax) parameter for AUC prediction for pravastatin and simvastatin. Drug Research 66(2):82-93.
  237. Srinivas NR (2015) Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate. Journal of Pain and Palliative Care Pharmacotherapy 29(3):272-275.
  238. Srinivas NR (2017) Differences in the prediction of area under the curve for a protease inhibitor using trough versus peak concentration: Feasibility assessment using published pharmacokinetic data for indinavir. American Journal of Therapeutics 24(4):e405-e418.
  239. Srinivas NR (2015) Recent trends in the preclinical drug-drug interaction potential of flavonoids –Physiological considerations, Issues and perspectives Phytotherapy Research, 29(11):1679-1691.
  240. Srinivas NR (2015) Fidaxomicin pharmacokinetics in humans: Is there a role of biliary excretion? Clinical Drug Investigation 35(8):531-532.
  241. Srinivas NR (2015) First in man study of ACT-453859, a potent CRTH2 antagonist – is the metabolite formation influenced by a polymorphic enzyme? Journal of Clinical Pharmacology 55(12):1432.
  242. Srinivas NR (2015) Comment on “Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. Am J Cardiovasc Drugs. American Journal of Cardiovascular Drugs 15(5):371-372.
  243. Srinivas NR (2015) Oral tramadol pharmacokinetics in pediatric subjects vs adults – Is there a role of delayed gastric emptying in pediatric subjects? Clinical Pharmacology and Drug Development 4(6):473-474.
  244. Mullangi R, Srinivas NR (2015). Bioanalysis in oncology drug discovery. Biomarkers in Medicine 9(9):877-886.
  245. Srinivas NR (2015) Gluten digestion in the stomach and duodenum by Aspergillus niger-derived enzyme – Things to ponder. Alimentary Pharmacology and Therapeutics 42(7):946.
  246. Srinivas NR (2016) Commonality of rituximab pharmacokinetic disposition in nephrotic syndrome and autoimmune cytopeneas in chronic lymphocytic leukemia patients. Pediatric Nephrology 31(2):335-336.
  247. Srinivas NR (2015) Physiologically based pharmacokinetic model for prediction of leflunomide and teriflunomide – should consideration be given to cannalicular efflux transporters? CPT: Pharmacometrics & Systems Pharmacology 4(10):563.
  248. Srinivas NR (2015) Infliximab therapy for patients with inflammatory bowel disease – Some unanswered questions. Alimentary Pharmacology and Therapeutics 42(9):1133.
  249. Srinivas NR (2016) The pharmacokinetic disposition of delta-9-tetrahydrocannabinol and its metabolite in elderly patients with dementia – Role of differential presystemic conversion? Pyschopharmacology 233(1):157-158.
  250. Srinivas NR (2016) Gastric emptying and acetaminophen: lessons learnt from the several co-administered drugs on the experimental design. European Journal of Clinical Pharmacology 72(3):369-371.
  251. Gilibili RR, Bhamidipathi R, Mullangi R, Srinivas NR (2015) Retrospective and prospective human intravenous and oral pharmacokinetic projection of DPP-IV inhibitors using simple allometric principles – Case Studies of ABT-279, ABT-341, alogliptin, carmegliptin, sitagliptin and vildagliptin. Journal of Pharmacy and Pharmaceutical Sciences (18(3), 434 – 448.
  252. Srinivas NR (2015) Comment on: “Pharmacokinetics and Pharmacokinetic/ Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection” Clinical Pharmacokinetics 54(12):1293 – 1295.
  253. Srinivas NR (2015) Phenylephrine pharmacokinetics and first pass metabolism – what is an ideal pharmacokinetic surrogate? Clinical Drug Investigation (35(12):851-853.
  254. Srinivas NR (2016) Prediction of area under the concentration-time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavir-ritonavir therapy. American Journal of Health-System Pharmacy 73(6):376-385.
  255. Srinivas NR (2016) Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: Assessment using fexofenadine, itraconazole and losartan and metabolites. Drug Development and Industrial Pharmacy 42(6):945-957.
  256. Srinivas NR (2015) Linagliptin – Role in the reversal of Aβ mediated impairment of insulin signalling and reduced neurotoxicity in AD pathogenesis: Some considerations. CNS Neuroscience & Therapeutics 21(12):962-963.
  257. Srinivas NR (2018) Influence of morbid obesity on the clinical pharmacokinetics of various anti-infective agents: Re-appraisal using recent case studies, issues and dosing implications. American Journal of Therapeutics 25(2):e224-e246.
  258. Srinivas NR (2016) Prostaglandin E1 therapy with alprostadil and risk reduction of early hepatic cellular carcinoma after liver transplantation. Alimentary Pharmacology and Therapeutics 43(1):172-173.
  259. Srinivas NR (2016) The interesting case of acyclovir delivered using chitosan in humans: Is it a drug issue or formulation issue? Pharmaceutical Research 33(3):543-547.
  260. Srinivas NR (2015) Schedule dependent modulation of the pharmacokinetics of MK-2206, an oral pan-AKT inhibitor: Perspectives. Cancer Chemotherapy and Pharmacology 76(6):1315-1316.
  261. Srinivas NR (2016) ‘Is there a differential conversion of artesunate to dihydroartemisinin in pregnant vs. post-partum patients with malaria after oral artesunate dosing? British Journal of Clinical Pharmacology 81(2):389-390.
  262. Srinivas NR (2016) Vonoprazan, a long lasting acid suppressor in the gastric H+, K+-ATPases ATPase: Implications for renal H+,K+-ATPases. Alimentary Pharmacology and Therapeutics 43(3):442-443.
  263. Srinivas NR (2016) Interspecies scaling of excretory amounts using allometry – Retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion. Xenobiotica 46(9):784-792.
  264. Srinivas NR (2016) Stereoselective tissue distribution of ketolorac in rats – differential uptake of ketolorac enantiomers in certain tissues. Drug Research 66(5):279-280.
  265. Srinivas NR (2016) Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters. General Physiology and Biophysics 35(3):243-258.
  266. Srinivas NR, Muzeeb S (2016) Intranasal pharmacokinetic data for triptans such as sumatriptan and zolmitriptan can render area under the curve (AUC) predictions for oral route: Strategy development and application. Journal of Pain and Palliative Care Pharmacotherapy 30(1):13-24.
  267. Srinivas NR, Muzeeb S (2016) Applicability of a single time point strategy for the prediction of area under the concentration curve of linezolid in patients: Superiority of Ctrough vs Cmax derived linear regression models. Drugs in R&D 16(1):69-79.
  268. Srinivas NR (2016) Relationship between buprenorphine dosing and triglyceride lowering and creatinine kinase elevation in felines: Possible human implications. Pain and Palliative Care Pharmacotherapy 30(1):49-52.
  269. Srinivas NR (2016) Enantioselective pharmacokinetics of bambuterol in preclinical species – Does S-bambuterol influence the clearance of the R-antipode? European Journal of Drug Metabolism and Pharmacokinetics 41(2):197-198.
  270. Srinivas NR (2016) Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV – Some considerations. Antiviral Therapy 21(7):647-648.
  271. Suresh, Srinivas NR and Mullangi R (2016) A concise review of the bioanalytical methods for the quantitation of sitagliptin, an important dipeptidyl peptidase-4 (DPP4) inhibitor, utilized for the pharmacokinetic characterization of the drug. Biomedical Chromatography 30(5):749-771.
  272. Syed M, Srinivas NR. (2016) A comprehensive review of the published assays for the quantitation of the immunosuppressant drug mycophenolic acid and its glucuronidated metabolites in biological fluids. Biomed Chromatogr 30(5):721-748.
  273. Srinivas NR (2016). Prediction of micafungin area under the curve data by using peak concentraton: Applicability and utility in antifungal therapy. Future Microbiology 11(4):485-490.
  274. Desai RC, Bahekar R, Prajapati V, Chopade R, Jain MR, Pawar V, Prajapati K, Patel R, Sonara B, Bhatnagar U, Bandyopadhyay D, Rami BR, Srinivas NR, Patel H, Giri P, Patel PR (2017). ZYKR1: A novel short chain peptide based peripherally restricted kappa (k) opioid receptors (KOR) agonist. 34th European Peptide Symposium, 4th to 9th Sept 2016, Leipzig Germany.
  275. Srinivas NR (2016). Transdermal rivastigmine delivery for Alzheimer’s disease: Amenability of exposure predictions of rivastigmine and metabolite, NAP226-90, by linear regression model using limited samples. Clinical Neuropharmacology 39(4):169-177.
  276. Suresh PS, Devaraj VC, Srinivas NR, Mullangi R (2017) Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belonistat, panobinostat, romidepsin and chidamine. Biomed Chromatogr. 31(1):e3807.
  277. Srinivas NR (2016) Predictions of the Pharmacokinetics in Burn Injury Patients using Regression Models – Case Study with Levofloxacin. Drug Res 66(10):555-560.
  278. Srinivas NR (2016) Verapamil and pristimerin pharmacokinetic drug-drug interaction study in rats – perspectives. Biomed Chromatogr. 30(12):2074.
  279. Soni K, Bhatt C, Singh K, Bhuvaneshwari PC, Jha A, Patel P, Patel H, Srinivas NR (2017) An LC-MS/MS assay for the quantitative determination of 2-pyridyl acetic acid, a major metabolite and key surrogate for betahistine, using low-volume human K2 EDTA plasma. Biomed Chromatogr. 31(2):e3790.
  280. Srinivas NR (2017) Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives. Xenobiotica 47(4):354-368.
  281. Srinivas NR (2016) Letter: probing the consequences of potent acid inhibition by vonoprazan. Aliment Pharmacol Therapeutics 44(3):304-305.
  282. Ghoghari A, Dash R, Bhatt C, Singh K, Jha A, Patel H, Gupta R, Kansagra K, Srinivas NR (2016) Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode. Biomed Chromatogr. 30(12):1900-1907.
  283. Srinivas NR (2016) Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing? Cancer Chemother Pharmacol. 78(5):1097-1098.
  284. Srinivas NR (2016) Dual Incorporation of the in vitro Data (IC50) and in vivo (Cmax) Data for the Prediction of Area Under the Curve (AUC) for Statins using Regression Models Developed for Either Pravastatin or Simvastatin. Drug Res (Stuttg). 66(8):402-406.
  285. Srinivas NR (2016) Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Aliment Pharmacol Ther. 43(11):1239-1240.
  286. Srinivas NR (2015) Oral tramadol pharmacokinetics in pediatric subjects versus adults-Is there a role of delayed gastric emptying in pediatric subjects? Clin Pharmacol Drug Dev. 4(6):473-474.
  287. Srinivas NR, Richter W, Devaraj VC, Suresh PS, Bhamdipati RK, Mullangi R (2016) Infusion Rate Dependent Pharmacokinetics of Bendamustine with Altered Formation of γ-hydroxybendamustine (M3) Metabolite Following 30- and 60-min Infusion of Bendamustine in Rats. Drug Res (Stuttg). 66(7):351-356.
  288. Srinivas NR (2016) Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms. Drugs R D. 16(2):141-148.
  289. Bhamidipati RK, Mullangi R, Srinivas NR (2017) Interspecies scaling of urinary excretory amounts of nine drugs belonging to different therapeutic areas with diverse chemical structures – accurate prediction of the human urinary excretory amounts. Xenobiotica 47(2):112-118.
  290. Sulochana SP, Syed M, Chandrasekar DV, Mullangi R, Srinivas NR (2016) Clinical Drug-Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives. Eur J Drug Metab Pharmacokinet. 41(5):469-503.
  291. Patel H Giri P, Ghoghari A, Delvadia P, Syed M, Srinivas NR (2016) Review of the bioanalytical methods for the determination of methotrexate and its metabolites in in vitro, preclinical and clinical studies: Case studies and perspectives. Biomedical Chromatography 31(1):e3849.
  292. Patel H, Giri P, Srinivas NR (2016) Review of pharmacokinetic data of different drug classes in Goto-Kakizaki rats, a non-obese model for type 2 diabetes mellitus: Case studies and perspectives. European Journal of Drug Metabolism and Pharmacokinetics 42(2):173-182.
  293. Srinivas NR. (2017) Comment on: “Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer. Clinical Pharmacokinetics 56(2):211-212.
  294. Srinivas NR (2016) Comparative safety and efficacy of infliximab versus adalimumab in Crohn’s disease: Should one consider disease location? Alimentary Pharmacology and Therapeutics 44(7):771-772.
  295. Soni K, Patel N, Singh K, Jha A, Patel H, Gupta R, Srinivas NR (2016) A sensitive triple quadruple liquid chromatography mass spectrometric method for the estimation of valproic acid in K2EDTA human plasma using furosemide as the internal standard. Drug Research 66(12):666-672.
  296. Srinivas NR (2016) Is there saturation in the conversion of baicalein to baicalin after oral chewable tablets – retrospective evaluation of the human pharmacokinetic data? Clinical Drug Investigation 36(12):1075-1076. 82.
  297. Srinivas NR (2017) Clinical food effect study in early drug development – Timing conundrum. International Journal of Pharmacokinetics 2(1):11-13.
  298. Srinivas NR (2017) Comment on: “A single dose-escalation study to evaluate the safety and pharmacokinetics of orally administered des-aspartate angiotensin I in healthy subjects”. Drugs R & D 17(1):241-242.
  299. Giri P, Naidu S, Patel N, Patel H, Srinivas NR (2017) Evaluation of in vitro cytochrome P450 inhibition and in vitro fate of structurally diverse N-oxide metabolites: Case studies with clozapine, levofloxacin, roflumilast, voriconazole and zopiclone. European Journal of Drug Metabolism and Pharmacokinetics 42(4):677-688.
  300. Dash RP, Babu RJ, Srinivas NR (2017) Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. Xenobiotica 47(11):1015-1026.
  301. Patel H, Joharapurkar AA, Bahekar R, Patel P, Kshirsagar SG, Modi N, Ghoghari A, Patel VJ, Jain MR, Srinivas NR, Patel PR, Desai RC (2016) Is the inhibition of dipeptidyl peptidase-4 (DPP-4) enzyme route dependent and/or driven by high peak concentration? Seeking answers with ZYDPL1, a novel long acting DPP-4 inhibitor, in a rodent model. Drug Research 67(4):223-227.
  302. Dash RP, Srinivas NR (2017) Stereoselective conversion of ketoprofen in men versus women from two different oral dosage formulations – Observations and introspection of the pharmacokinetic data. European Journal of Drug Metabolism Pharmacokinetics 42(1):165-166.
  303. Giri P, Delvadia P, Gupta L, Patel N, Trivedi P, Lad K, Patel HM, Srinivas NR (2018) Consequences of daily corticosteroid dosing with or without pre-treatment with quinidine on the in vivo cytochrome P450 2D (CYP2D) enzyme in rats: Effect on O-demethylation activity of dextromethorphan and expression levels of CYP2D1 mRNA. Xenobiotica 48(1):1-10.
  304. Dash RP, Babu RJ, Srinivas NR (2018) Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica 48(1):89-108.
  305. Patel H, Joharapurkar AA, Bahekar R, Patel P, Kshirsagar SG, Modi N, Ghoghari A, Patel VJ, Jain MR, Srinivas NR, Patel PR, Desai RC. (2018). Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia. Xenobiotica 48(1):37-44.
  306. Srinivas NR (2017) Preclinical pharmacokinetics of novel trioxane antimalarial drug (99/411) – Several unanswered questions and development perspectives. Biomedical Chromatography 31(8):e3938.
  307. Patel H, Ghoghari A, Bhatt C, Shah S, Jha A, Desai N, Srinivas NR. (2017) A sensitive quantitative assay for the simultaneous determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in a positive mode. Biomedical Chromatography 31(10):e3967.
  308. Dash RP, Babu RJ, Srinivas NR (2017) Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic – Infectious Diseases 49(7):483-492.
  309. Patel H, Patel P, Bhatt C, Ghoghari A, Patel U, Ukawala M, Sheikh S, Ramanathan V, Srinivas NR. (2017) Comparative pharmacokinetics of cholecalciferol in dogs from two different oral formulations using corrective measures to overcome interference from endogenous cholecalciferol. Drug Research (Stutg) 67(7):388-395.
  310. Bhamidipati RK, Syed M, Mullangi R, Srinivas NR. (2018). Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models. Xenobiotica 48(2):148-156.
  311. Srinivas NR (2017) Duration of action of insulin products in diabetic mellitus patients – Possible implications on Bio-similarity assessment. Journal of Bioequivalence and Bioavailability 9(2):e75.
  312. Giri P, Patel N, Patel B, Patel H, Bahekar R, Srinivas NR, Patel PR, Desai R (2017) Highly Sensitive LC-ESI-MS/MS Method for Determination of ZYDPLA1, a Novel long acting DPP4 Inhibitor in Rat Plasma: Application to a Pharmacokinetic Study in Rats. Biomedical Chromatography 31(11):e3984.
  313. Patel H, Soni K, Trivedi R, Heading H, Geue J, Kansagra K, Gupta RJ, Pandya VB, Srinivas NR, Patel PR, Desai RC (2017) A sensitive assay for ZYAN1 in human whole blood and urine utilizing positive LC-MS/MS electrospray ionization. Bioanalysis 9(9):719-732.
  314. Srinivas NR (2017) Use of vitamin D3 in inflammatory bowel disease (IBD) patients: The on-going saga. Journal of Inflammatory Bowel Diseases & Disorders 2(1): e104.
  315. Dash RP, Babu RJ, Srinivas NR (2017). Therapeutic potential and utility of elacridar with respect to P-glycoprotein inhibition: An insight from the published in vitro, preclinical and clinical studies. European Journal of Drug Metabolism and Pharmacokinetics 42(6):915-933.
  316. Kansagra KA, Parmar D, Jani RH, Srinivas NR, Lickliter J, Patel HV, Parikh DP, Heading H, Patel HB, Gupta RG, Shah CY, Patel MR, Dholakia V, Chauhan H, Jain MR, Parmar KV, Barot K. (2018) Phase I clinical study of ZYAN1, a novel PHD-2 inhibitor, to evaluate the safety, tolerability, pharmacokinetics following oral administration in healthy volunteers. Clinical Pharmacokinetics 57(1):87-102.
  317. Giri P, Patel H, Srinivas NR. (2017). Human biliary amount prediction using Simple, bile flow-rate corrected and UDPGT activity corrected allometric methods – International Journal of Pharmacokinetics 2(3):173-182.
  318. Dash RP, Rais R, Srinivas NR (2018) Stereoselective and non-stereoselective pharmacokinetics of rabeprazole – An overview. Xenobiotica 48(4):422-432. 320.
  319. Srinivas NR (2017) Sublingual dosing of tacrolimus in transplant patients – interesting concept to overcome first pass effects. Alimentary Pharmacology and Therapeutics 46(1):79-80.
  320. Chandrasekhar DV, Suresh P S Rajnish Kumar, Ravi Bhamidipati RK, Mullangi R, Richter W, Srinivas NR (2017) Sensitive LC-MS/MS method for the simultaneous determination of bendamustine and its active metabolite, γ-hydroxybendamustine in small volume mice and dog plasma and its application to a pharmacokinetic study in mice and dogs. Drug Research 67(9):497-508.
  321. Srinivas NR (2017) Intravenous to oral switch in antimicrobial therapy – clinical pharmacology considerations and perspectives. Future Microbiology 12:847-851.
  322. Srinivas NR (2017) Severe metabolic impairment with increasing age for CYP3A and CYP2D substrates in rats – Possible consequences for drug development. Biomedical Chromatography 31(12).
  323. Dash RP, Rais R, Srinivas NR (2018) Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: Review of clinical pharmacokinetics and drug disposition. Xenobiotica 48(5):442-451.
  324. Srinivas NR (2017) Clinical response to pioglitazone in nonalcoholic steatohepatitis [NASH] treatment – Use of pharmacokinetic surrogate. Alimentary Pharmacology and Therapeutics 46(4):470-471.
  325. Srinivas NR (2017) Pharmacodynamics of Insulin preparations administered in different subcutaneous injection sites – Are there differences between healthy subjects vs. diabetic patients? Clinical Drug Investigation 37(9):881-884.
  326. Srinivas NR (2017) Improved oral bioavailability and brain accumulation of afatinib due to dual inhibition of the efflux mechanisms of BCRP and Pgp transporters – What next? Pharmacological Research 123:143.
  327. Patel H, Patel P, Modi N, Shah S, Ghoghari A, Variya B, Laddha R, Baradia D, Doaria N, Mehta P, Srinivas NR (2017). One should avoid retro-orbital pharmacokinetic sample collections for intranasal dosing in rats: Illustration of spurious pharmacokinetics generated for anti-migraine drugs zolmitriptan and eletriptan. European Journal of Pharmaceutical Sciences 106:87-93.
  328. Srinivas NR (2017) CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury. Alimentary Pharmacology and Therapeutics 46(7):706-707.
  329. Dash RP, Rais R, Srinivas NR (2018) Key pharmacokinetic essentials of fixed dosed combination products – Case studies and perspectives. Clinical Pharmacokinetics 57(4):419-426.
  330. Suresh PS, Srinivas NR, Mullangi R (2018). Review of HPLC and LC-MS/MS assays for the determination of various non-steroidal anti-androgens used in the treatment of prostate cancer. Biomedical Chromatography 32(1).
  331. Chandrasekhar DV, Suresh P S, Dittakavi S, Hiremath RA, Bhamidipati RK, Richter W, Srinivas NR, Mullangi R (2018) LC-ESI-MS/MS determination of 4-methylpyrazole in dog plasma and its application to a pharmacokinetic study in dogs. Biomedical Chromatography 32(2).
  332. Srinivas NR (2017) Comments on: “Population pharmacokinetic modeling of olmesartan, the active metabolite of olmesartan medoxomil, in patients with hypertension. European Journal of Drug Metabolism and Pharmacokinetics 42(6):1019-1021.
  333. Srinivas NR (2018) Arenobufagin: A potential novel opportunity for prostate cancer treatment – Intriguing mechanistic data but some questions on in vivo translatability. Pharmacological Research 128:400-401.
  334. Dash RP, Rais R, Srinivas NR (2017) Chirality and neuropsychiatric drugs – An update on stereoselective disposition and clinical pharmacokinetics of bupropion. Xenobiotica 48(9):945-957.
  335. Srinivas NR (2017) Comments on:”In vitro and in vivo pharmacokinetics and toxicity evaluation of curcumin incorporated titanium dioxide nanoparticles for biomedical applications” Chemico-Biological Interactions 277:145.
  336. Dash RP, Srinivas NR, Rana R (2018). Review of bioanalytical quantitative methods for selected sphingosine 1-phosphate (S1P1) receptor modulators. Biomedical Chromatography 32:1.
  337. Patel MR, Kansagra K, Devang P, Parmar D, Patel H, Mayur S, Patil U, Patel H, Patel J, Gujrathi S, Parmar K, Srinivas NR (2018) Effect of food on the oral bioavailability and pharmacokinetics of saroglitazar magnesium, a novel dual PPAR αγ agonist, in healthy adult subjects. Clinical Drug Investigation 38(1):57-65.
  338. Patel H, Giri P, Patel P Gupta L, Patel U, Modi N, Shah K, Jain MR, Srinivas NR, Patel PR (2018). Preclinical evaluation of Saroglitazar Magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders. Xenobiotica (48(12):1268-1277.
  339. Srinivas NR (2018) Anti-retroviral therapy with efavirenz in HIV infected pregnant women – understanding the possible mechanisms for drug-drug interaction. Clinical Pharmacology and Therapeutics 103(4):570.
  340. Srinivas NR (2018) High oral dose of taurine for portal hypertension in cirrhotic patients – some clinical pharmacology considerations. Alimentary Pharmacology and Therapeutics 47(6):861-862.
  341. Giri P, Joshi S, Srinivas NR. (2018) Linear regression modeling strategy for prediction of area under the curve data of evogliptin, a novel DPP IV inhibitor in humans, using single dose pharmacokinetic data. International Journal of Pharmacokinetics 3(1):23-38.
  342. Srinivas NR (2018) Lack of translatable pro-inflammatory cytokines in cerebrospinal fluid in rats with increased hyperalgesia with or without fentanyl treatment. Anaesthesia and Analgesia 126(6):2150.
  343. Srinivas NR (2018) Debate on bioavailability and bioequivalence (BA/BE) studies using limited sampling strategy – Views and perspectives. Journal of Bioequivalence and Bioavailability 10(1):e82.
  344. Poonam G, Patel H, Srinivas NR (2017) Effect of short-term fasting on systemic cytochrome P450-mediated drug metabolism in healthy subjects: Journal of Applied Biopharmaceutics and Pharmacokinetics 5:26-29.
  345. Joshi S, Srinivas NR, Parmar D (2018) Limited sampling strategy for accurate prediction of pharmacokinetics of saroglitazar – A 3-point linear regression model development and successful prediction of human exposure. Clinical Therapeutics 40(3):456-468.
  346. Kansagra KA, Parmar DV, Patel MR, Srinivas NR (2018) Lack of Sex Differences in the Pharmacokinetics of Saroglitazar Magnesium in Healthy Subjects. SL Pharmacol Toxicol. 2018; 1(1):111
  347. Srinivas NR (2018) Improved oral bioavailability and variability control in pharmacokinetic data – Role of formulations. Journal of Bioequivalence and Bioavailability 10(1):e84.
  348. Tripathi P, Patel H, Kulshrestha T, Srinivas NR (2018) Standard curve range for clinical sample analysis of oral bioavailability/bioequivalence studies – Dilemma, introspection and strategies. Bioanalysis 10(10):717-722.
  349. Srinivas NR (2018) Drug Combination Strategy: Pharmacokinetics and Drug-Drug Interaction Considerations in Diseased Patients. J Bioequiv. Bioavailability 10(3):e87.
  350. Srinivas NR (2018) Reduced ketobemidone usage in quadratus lumborum (QL) block patients after Cesarean delivery – clinical pharmacology views. Anaesthesia and Analgesia 127(1):311.
  351. Srinivas NR (2018) Pharmacology of pimasertib, a selective MEK1/2 inhibitor. European Journal of Drug Metabolism and Pharmacokinetics 43(4):373-382.
  352. Srinivas NR (2018) Clinical pharmacology considerations for development of β-lactamase inhibitor combination with antibiotics. Drug Research 68(9):536-540.
  353. Giri P, Trivedi P, Lad K, Delvadia P, Joshi V, Srinivas NR (2018) Opposite effects of acute kidney injury on pharmacokinetics of renally and hepatobiliary excreted drugs. International Journal of Pharmacokinetics 3(2):81-90.
  354. Dash RP, Rais R, Srinivas NR (2018) Review of clinical pharmacokinetics of levofloxacin with special emphasis in burn injury patients. Book Chapter (Springer Publishers in press).
  355. Dash RP, Babu JD, Srinivas NR (2018) Two decades long journey from riluzole to edaravone: Revisiting the clinical pharmacokinetics of the only two Amyotrophic Lateral Sclerosis (ALS) therapeutics. Clinical Pharmacokinetics 57(11):1385-1398.
  356. Patel H, Patel P, Modi N, Patel PM, Wagh Y, George A, Srinivas NR (2017) Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: Case study with paliperidone palmitate suspension. Xenobiotica 49(4):415-421.
  357. Jairam RK, Mallurwar SR, Suresh PS, Bhamidipati RK, Richter W, Srinivas NR and Mullangi R (2019) Prediction of Human Pharmacokinetics of Bendamustine from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles. Drug Research 69(1):32-39.
  358. Giri P, Delvadia P, Gupta L, Trivedi P, Patel N, Sharma M, Singh J, Chatterjee A, Kadam S, Srinivas NR (2019) Impact of collagen-induced arthritis on the pharmacokinetic disposition of voriconazole, a widely used antifungal agent: In vitro and in vivo investigations in DBA/1J mice. Xenobiotica 49(6):698-707.
  359. Giri P, Patel H, Srinivas NR (2019). Review of clinical pharmacokinetics of avibactam, a newly approved non-β lactam β-lactamase drug, in combination use with ceftazidime. Drug Research 69(5):245-255.
  360. Jain M, Chatterjee A, Mahapatra J, Patel D, Srivastava B, Shedage S, Kadam P, Bandyopadhyay D, Ghoshdastidar K, Sundar R, Patel H, Giri P, Patel P, Gupta L, Srinivas NR, Patel P, Desai R (2018) Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) and tankyrase inhibitor ZYTP1. Cancer Pharmacology and Therapeutics 82(4):635-647.
  361. Dash RP, Babu RJ, Srinivas NR (2018). Non-alcoholic steatohepatitis (NASH) drug discovery –Building a consensus on ADME screening tools and clinical pharmacology strategies to aid candidate development. Journal of Pharmacy and Pharmaceutical Sciences 21(1):481-495.
  362. Giri P, Gupta L, Naidu S, Joshi V, Patel N, Giri S, Srinivas NR. (2018) In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metabolism Letters 12(2):101-116.
  363. Giri P, Patel H, Srinivas NR (2019) Use of cocktail probe drugs for indexing cytochrome P450 enzymes in clinical pharmacology studies – Review of case studies. Drug Metabolism Letters 13(1):3-18.
  364. Giri P, Patel N, Joshi V, Giri S, Srinivas NR (2019) Incurred sample reanalysis in drug discovery bioanalysis: Perspectives. Biomedical Chromatography 33(3):e4430.
  365. Giri P, Gupta L, Singh S, Patel N, Srinivas NR, Srivastva BK, Desai RC, Patel PR (2019) Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of ZYTP1, a novel poly (ADP-ribose) polymerase inhibitor. Xenobiotica 49(10):1164-1172.
  366. Patel H, Desai N, Patel P, Modi N, Soni K, Dobaria N, Srinivas NR (2019) Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. Xenobiotica 49(10):1202-1208.
  367. Patel H, Desai N, Patel P, Modi N, Soni K, Patel JR, Mistry GN, Patel JD, Chawla M, Srinivas NR (2018) Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs. Drug Dev Ind Pharm. 45(9):1459-1467.
  368. Giri P, Delvadia P, Ladani MK, Prajapati N, Gupta L, Patel N, Joshi V, Giri S, Jain MR, Srinivas NR, Patel PR (2019) Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. Eur J Pharm Sci. 130:107-113.
  369. Srinivas NR (2018) Extrapolation of PK interaction data of proton pump inhibitors in healthy subjects for oral targeted cancer therapies. International Journal of Pharmacokinetics (in press).
  370. Suresh PS, Srinivas NR, Mullangi R (2019) Review of DBS methods as a quantitative tool for anticancer drugs. Biomedical Chromatography 33(1):e4445.
  371. Srinivas NR (2019) Strategy for the prediction of steady state exposure of digoxin to determine drug-drug interaction potential of digoxin with other drugs in digitalization therapy. American Journal of Therapeutics 26(1):e54–e65.
  372. Srinivas NR (2019) Comment on: Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: First-in-human phase I study. Clinical Drug Investigation 39(1):105-107.
  373. Jairam RK, Mallurwar SR, Sulochana SP, Chandrasekhar DV, Todmal U, Bhamidipati RK, Richter W, Srinivas NR, Mullangi R (2019) Prediction of human pharmacokinetics of fomepizole from preclinical species pharmacokinetics based on normalizing time course profiles. AAPS PharmSciTech. 20(6):221.
  374. Kumar Saini N, Sulochana SP, Kiran V, Rangnathrao Mallurwar S, Richter W, Srinivas NR, Mullangi R (2019) Simultaneous determination of bendamustine and γ-hydroxybendamustine in mice dried blood spots and its application in a mice pharmacokinetic study. J Pharm Biomed Anal. 174:168-174.
  375. Alrbyawi H, Poudel I, Dash RP, Srinivas NR, Tiwari AK, Arnold RD, Babu RJ (2019) Role of ceramides in drug delivery. AAPS PharmSciTech. 20(7):287.
  376. Dash RP, Srinivas NR, Babu RJ (2019) Use of sorbitol as pharmaceutical excipient in the present day formulations – issues and challenges for drug absorption and bioavailability. Drug Dev Ind Pharm. 45(9):1421-1429.
  377. Srinivas NR (2019) Combination of flavonoids with azole drugs for fungal infections: key pharmacokinetic challenges. Future Microbiol 14:733-738.
  378. Mulabagal V, Annaji M, Kurapati S, Dash RP, Srinivas NR, Tiwari AK, Babu RJ (2020) Stability-indicating HPLC method for acyclovir and lidocaine in topical formulations. Biomedical Chromatography 34(3):e4751.
  379. Gabani BB, Todmal U, Saini NK, Balakrishna VA, Sulochana SP, Timmapuram A, Zainuddin M, Balaji N, Shuvranshu P, Srinivas NR, Mullangi R (2020) Stereoselective pharmacokinetics and tissue distribution of levodropropizine after administration of pure levodropropizine and the rac-dropropizine to Sprague-Dawley rats. Xenobiotica. 50(2):135-144].
  380. Srinivas NR (2020) Stereoselective pharmacokinetic disposition of ketorolac following drug administration to periarticular tissues in patients. Anaesthesia and Analgesia 130(1):e33-e34.
  381. Sulochana PS, Trivedi R, Srinivas NR, Mullangi R (2020) A review of bioanalytical methods for chronic lymphocytic leukemia drugs and metabolites in biological matrices. Biomedical Chromatography 34(1):e4742.
  382. Gabani BB, Kiran V, Praharaj S, Srinivas NR, Mullangi R (2020) Incurred sample reanalysis (ISR) of cefuroxime in rabbit ocular tissues – A case study. Biomedical Chromatography 34(2):e4737.
  383. Srinivas NR (2020) Pronounced influence of presystemic metabolism on the metabolic disposition of imrecoxib in renally impaired patients. European Journal of Clinical Pharmacology 76(3):469-471.
  384. Srinivas NR (2020) International normalized ratio (INR) dependent clearance of dexmedetomidine: Possible clinical implications. Anaesthesia and Analgesia 130(5):e153.
  385. Saini NK, Gabania BB, Todmala U, Sulochana SP, Zainuddin M, Balaji N, Polin SB, Srinivas NR, Mullangi R (2020) Pharmacokinetics of darolutamide in mouse – Assessment of the disposition of the diastereomers, key active metabolite and interconversion phenomenon: Implications to cancer patients. Drug Metabolism and Letters (online -ahead of print).
  386. Giri P, Delvadia P, Ladani MK, Prajapati N, Gupta L, Jain MR, Srinivas NR (2020) Relevance of preclinical rodent pharmacokinetics in the selection of a companion antibiotic for combining with beta-lactamase inhibitor. Xenobiotica 50(7):815-821.
  387. Gabani BB, Saini NK, Jairam RK, Shrinivas P, Trivedi RK, Srinivas NR, Mullangi R (2020). Simultaneous determination of colchicine and febuxostat in rat plasma: Application in a rat pharmacokinetic study. Biomed Chromatogr.:e4939 (online ahead of print).
  388. Dash RP, Thomas JA, Rosenfeld C, Srinivas NR (2020) Protein Binding and Stability: The Achilles’ Heel in the In vitro Potency Assays. European Journal of Drug Metabolism and Pharmacokinetics 45(4):427-432.
  389. Veeravali V, Dash RP, Thomas JA, Babu RJ, Madgula LMV, Srinivas NR (2020) Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib, and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Safety 43(8):711-725.
  390. Jairam RK, Mallurwar SR, Gabani BB, Zakkula A, Kiran V, Sulochana SP, Zainuddin M, Srinivas NR and Mullangi R. (2020). Ocular tissue uptake and pharmacokinetics of cefuroxime in rabbits after intravitreal, intracameral and topical dosing – Relevance to human ocular injection of cefuroxime. Xenobiotica 50(3):339-345.
  391. . Ghoshdastidar K, Patel H, Bhayani H, Patel A, Thakkar K, Patel D, Sharma M, Singh J, Mohapatra J, Chatterjee A, Patel D, Bahekar R, Sharma R, Gupta L, Patel N, Giri P, Srinivas NR, Jain M, Bandyopadhyay D, Patel PR, Desai RC (2020). ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer. Pharmacol Res Perspect. 8(4):e00565.
  392. Kiran V, Dixit A, Gabani BB, Srinivas NR, Mullangi R (2020) Novel methodology to perform incurred sample reanalysis (ISR) on dried blood spot (DBS) cards – Experimental data using darolutamide and filgotinib. Biomedical Chromatography e4938 (Epub ahead of print).
  393. Kiran V, Balaji N, Gabani BB, Bajantri M, Chandran R, Dixit A, Srinivas NR, Mullangi R (2020) Enantioselective LC-ESI-MS/MS method for quantitation of (-)-lumefantrine and (+)-lumefantrine in mice plasma and application to a pharmacokinetic study. Biomed Chromatogr 34(9):e4879.
  394. Gabani BB, Dixit A, Kiran V, Bestha RM, Balaji N, Srinivas NR, Mullangi R (2020) Enantioselective in vitro ADME, absolute oral bioavailability and pharmacokinetics of (-)-lumefantrine and (+)-lumefantrine in mice. Xenobiotica (in press).
  395. Trivedi RK, Sulochana SP, Srinivas NR, Mullangi R (2020) A concise review of bioanalytical methods of small molecule immune-oncology drugs in cancer therapy. Biomedical Chromatography (in press)
  396. Kurakula M, Chen L, Tiwari A, Srinivas NR, Dash RP, Panizzi PR, Arnold RD, Babu RJ (2020) Recent Advances in Lipid-based Nanovesicular Delivery Systems for Melanoma Therapy. Critical Reviews Therapeutic Drug Carrier Systems (in press)
  397. Dash RD, Veeravalli V, Thomas JA, Rosenfeld C, Mehta N, Srinivas NR (2020) Blood or Plasma: What is the ideal matrix for pharmacokinetic driven drug candidate selection? Future Medicinal Chemistry (in press).
Nils Bundgaard

Nils Bundgaard

Modeling & Simulation Scientist

Bio

Nils Bundgaard comes from an interdisciplinary background having studied Molecular Medicine (B. Sc) and Systems Biology (M. Sc.). In his Master studies he has gained extensive knowledge in Infectious disease and Immunity, Neuroscience and Cancer biology. He has experience in building multiscale models combining agent-based and mechanistic modelling using likelihood-free parameter estimation for parameterization on high performance computing cluster environments. He joined IntiQuan in August 2021.

Coming soon

Lydia Burgert, PhD

Lydia Burgert, PhD

Modelling and Simulation Scientist

Bio

Lydia Burgert is a diversely trained modeler with a background in biotechnology (B. Sc.) and epidemiology (M. Sc.). Lydia received her PhD at the Swiss Tropical and Public Health Institute and the University of Basel in close collaboration with the Medicines for Malaria Venture. Her research focused on using mathematical modelling to support the development of new antimalarial drugs. She employed different approaches including pharmacometric analysis, agent-based models and machine learning methods to investigate the translation of antimalarial efficacy indices from translational drug development up to population impact. Before joining IntiQuan, she was responsible for the initiation of a multi-year project at the Tropical and Public Health Institute bringing together stakeholders from pharmaceutical industry,  academia, and global-health agencies to shape the target product profiles of future antimalarial interventions

Lydia is part of the IntiQuan team since September 2021.

Publications:

Burgert L, Rottmann M, Wittlin S, Gobeau N, Krause A, Dingemanse J, Möhrle JJ, Penny MA. Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development. Sci Rep. 2020 Mar 10;10(1):4410. doi: 10.1038/s41598-020-61304-8. PMID: 32157151; PMCID: PMC7064600.

Burgert L, Zaloumis S, Dini S, Marquart L, Cao P, Cherkaoui M, Gobeau N, McCarthy J, Simpson JA, Möhrle JJ, Penny MA. Parasite-Host Dynamics throughout Antimalarial Drug Development Stages Complicate the Translation of Parasite Clearance. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e01539-20. doi: 10.1128/AAC.01539-20. PMID: 33526486; PMCID: PMC8097426.

Camponovo F, Lee TE, Russell JR, Burgert L, Gerardin J, Penny MA. Mechanistic within-host models of the asexual Plasmodium falciparum infection: a review and analytical assessment. Malar J. 2021 Jul 10;20(1):309. doi: 10.1186/s12936-021-03813-z. PMID: 34246274; PMCID: PMC8272282.

Reiker T, Golumbeanu M, Shattock A, Burgert L, Smith TA, Filippi S, Cameron E, Penny Machine learning approaches to calibrate individual-based infectious disease models, medRxiv 2021.01.27.21250484; doi: https://doi.org/10.1101/2021.01.27.21250484 (accepted at Nature Communications)

Burgert et al. (2020), “Model informed target product profiles of long acting injectables for use as seasonal malaria prevention”, 2020 Annual Meeting American Society of Tropical Medicine and Hygiene

Burgert et al. (2020), “Investigation of parasite-host dynamics in antimalarial drug development reveals a disconnect in experimental endpoints”, 2020 Annual Meeting American Society of Tropical Medicine and Hygiene

Burgert (2019), “Ensemble modeling highlights importance of understanding parasite-host behaviour in preclinical antimalaria drug development“ (Talk), Epidemics7 – International Conference on Infectious Disease Dynamics, Charleston, USA

 

 

Franziska Weber, MD PhD

Franziska Weber, MD PhD

Medical Advisor

Bio

 

Publications:

Weber, F.D., Bielicki, J., Rodieux, F., van den Anker, J., and Pfister, M. Selb-stmedikation und Adhärenz in der Pädiatrie. Pädiatrie 04/2015, 2015.

Weber, F.D., Weinhofer, I., Einwich, A., Forss-Petter, S., Muneer, Z., Maier, H., Weber, W.H.A., and Berger, J. Evaluation of retinoids for induction of the redun-dant gene abcd2 as an alternative treatment option in x-linked adrenoleukodys-trophy. PLOS ONE, 2014.

Weber, F.D., Wiesinger, C., Forss-Petter, S., Regelsberger, G., Einwich, A., Weber, W.H.A., Köhler, W., Stockinger, H., and Berger, J. X-linked adrenoleukodystro-phy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes. Human Molecular Genetics, 2014.

Weber, F., Siska, P., Kramer, M., Zulehner, N., Hackl, S., and Wesierska-Gádek, J. Combining an fptase inhibitor with cisplatin facilitates induction of apoptosis in human a549 lung cancer cells. Journal of Experimental Therapeutics & Oncology, 2011.

LET'S EXPLORE HOW WE CAN BE HELPFUL

GET IN TOUCH